title: 2000/35/EF: Kommissionens beslutning af 16. december 1999 om EF-tilskud til dækning af Italiens udgifter til bekæmpelse af skadegørere på planter eller planteprodukter (meddelt under nummer K(1999) 4517) (Kun den italienske udgave er autentisk)

text: L 12/28 DA De Europæiske Fællesskabers Tidende 18. 1. 2000 KOMMISSIONENS BESLUTNING af 16. december 1999 om EF-tilskud til dækning af Italiens udgifter til bekæmpelse af skadegørere på planter eller planteprodukter (meddelt under nummer K(1999) 4517) (Kun den italienske udgave er autentisk) (2000/35/EF) KOMMISSIONEN FOR DE EUROPÆISKE FÆLLESSKABER HAR — under henvisning til traktaten om oprettelse af Det Europæiske Fællesskab, under henvisning til Rådets direktiv 77/93/EØF af 21. december 1976 om foranstaltninger mod indslæbning i Fælles- skabet af skadegørere på planter eller planteprodukter og mod deres spredning inden for Fællesskabet (1), senest ændret ved Kommissionens direktiv 1999/53/EF (2), særlig artikel 19, litra c), og ud fra følgende betragtninger: eller til yderligere foranstaltninger, der er taget eller vil blive taget, og som er nødvendige for at (realisere målsætningen om at) udrydde eller få de pågældende skadegørere under kontrol; et sådant bidrag ville være genstand for en efterfølgende beslutning; (7) (8) denne beslutning foregriber ikke resultatet af Kommis- sionens undersøgelse i henhold til artikel 19d i direktiv 77/93/EØF af, hvorvidt indslæbningen af den pågæl- dende skadegører skyldes utilstrækkelige undersøgelser eller kontrol, og konsekvenserne af Kommissionens undersøgelse; de i denne beslutning fastsatte foranstaltninger er i over- ensstemmelse med udtalelse fra Den Stående Komité for Plantesundhed — (1) (2) (3) (4) (5) (6) I henhold direktiv 77/93/EØF kan der ydes EF-tilskud til medlemsstaterne til dækning af direkte udgifter til nødvendige foranstaltninger, som er truffet eller plan- for at bekæmpe skadegørere, der er lægges truffet indslæbt fra tredjelande eller fra andre områder i EF, og i sidste ende udrydde dem eller, hvis det ikke er muligt, holde dem under kontrol; Italien har ansøgt om et sådant EF-tilskud og sendt et handlingsprogram for at udrydde Ralstonia solana- cearum (Smith) Yabuuchi et al. , det agens, der forårsager kartoffelbrunbakteriose, I indslæbt dette program redegøres der for mål, foranstaltninger, deres varighed og udgifterne hertil, så EF kan bidrage til at finansiere det; Italien i 1995. til EF-tilskuddet kan dække op til 50 % af de refusionsberet- tigede udgifter; de udgifter, som Italien har afholdt i 1995 og 1996, som blev taget i betragtning i denne beslutning, har direkte med plantesundhedskontrol, prøveudtagning og analyser af kartofler at gøre; på grundlag af de tekniske oplysninger fra Italien har Den Stående Komité for Plantesundhed kunnet foretage en præcis og udtømmende analyse af situationen; tilskuddet i artikel 2 er ikke til hinder for et eventuelt tilskud til yderligere udgifter, anført i ansøgningen fra Italien, men ikke taget i betragtning i denne beslutning, (1) EFT L 26 af 31. 1. 1977, s. 20. (2) EFT L 142 af 5. 6. 1999, s. 29. VEDTAGET FØLGENDE BESLUTNING: Artikel 1 Det godkendes, at der tildeles et EF-tilskud til dækning af Italiens direkte udgifter til nødvendige foranstaltninger som defineret i artikel 19c, stk. 2, i direktiv 77/93/EØF til bekæm- pelse af Ralstonia solanacearum. Artikel 2 EF-tilskuddet kan højst være på 18 365 EUR. Tilskuddet fordeles således: — 9 585 EUR til foranstaltninger til bekæmpelse af Ralstonia solanacearum i Veneto — 8 780 EUR til foranstaltninger til bekæmpelse af Ralstonia solanacearum i Emilia-Romagna. Artikel 3 1. Med forbehold af Kommissionens undersøgelser i henhold til artikel 19d, stk. 1 i direktiv 77/93/EØF udbetales EF-tilskuddet først, når Kommissionen har fået bevis for de foranstaltninger, der er truffet, i form af dokumentation vedrø- rende forekomsten og udryddelsen af Ralstonia solanacearum. 18. 1. 2000 DA De Europæiske Fællesskabers Tidende L 12/29 2. Den i stk. 1 nævnte dokumentation omfatter følgende: a) en udryddelsesrapport for hver bedrift, hvor der er destru- eret planter eller planteprodukter. Rapporten skal indeholde oplysning om: — bedriftens beliggenhed og adresse — datoen for, hvornår der opstod mistanke om forekom- sten af Ralstonia solanacearum, og datoen for, hvornår forekomsten blev bekræftet — mængden af destruerede planter og planteprodukter — destruktions- og desinfektionsmetoden — antallet af prøver, der er udtaget til undersøgelse og kontrol for forekomsten af Ralstonia solanacearum — kontrolmetoden — resultaterne af undersøgelser og/eller kontrol — formodet årsag til forekomsten i Italien b) en kontrolrapport om forekomsten af Ralstonia solana- cearum og om omfanget af kontamineringen med Ralstonia solanacearum, herunder nærmere oplysninger om, hvilken kontrol der er foretaget heraf c) en regnskabsrapport med en liste over modtagere og deres adresser samt det beløb, de har fået udbetalt (eksklusive moms og afgifter). Artikel 4 Denne beslutning er rettet til Den Italienske Republik. Udfærdiget i Bruxelles, den 16. december 1999. På Kommissionens vegne David BYRNE Medlem af Kommissionen


title: KIRJALLINEN KYSYMYS E-2428/99 esittäjä(t): Piia-Noora Kauppi (PPE-DE) komissiolle. Kilpa- ja harrastuskäytössä olevien hevosten sulkeminen eläinlääkintäsäännösten ulkopuolelle.

eurovoc_concepts:
consumer protection
domestic animal
equidae
horsemeat
leisure
meat processing industry
slaughter animal
sport
veterinary drug
veterinary legislation

formats: html pdf print

text: 8. 8. 2000 FI Euroopan yhteis(cid:246)jen virallinen lehti C 225 E/131 (2000/C 225 E/141) KIRJALLINEN KYSYMYS E-2421/99 esitt(cid:228)j(cid:228)(t): Sebastiano Musumeci (UEN) komissiolle (16. joulukuuta 1999) Aihe: Mehil(cid:228)ishoitajia rankaiseva hunajaa koskeva uusi direktiivi Komissio valmistautuu hyv(cid:228)ksym(cid:228)(cid:228)n direktiivin 74/409 (1) korvaavaa uutta direktiivi(cid:228) hunajasta. Direktiivi sellaisena, kun se on laadittu, rankaisisi ankarasti alan yritt(cid:228)ji(cid:228). Italian ja muiden Euroopan maiden mehil(cid:228)ishoitajat ovat esitt(cid:228)neet oikeutettuja vaatimuksia, jotka kohdistuvat ennen kaikkea seuraa- viin seikkoihin: 1. Hunajantuotanto pit(cid:228)isi rinnastaa maanviljelyksen kaltaiseen toimintaan, eik(cid:228) s(cid:228)ilyketeollisuuden edustajien lobbaukseen pit(cid:228)isi taipua, sill(cid:228) sen tavoitteena on aina ollut laatuvaatimusten alentaminen ja tuoteselosteessa vaadituista tiedoista tinkiminen. 2. Yksitt(cid:228)isill(cid:228) valtioilla pit(cid:228)isi olla oikeus suojella hunajaa tuotteena, joka on per(cid:228)isin ainoastaan kukkien medest(cid:228) ja est(cid:228)(cid:228) yhteis(cid:246)n ulkopuolisissa maissa tuotetun hunajan ja sekoitusten p(cid:228)(cid:228)sy Euroopan markkinoille, joka tapahtuu usein j(cid:228)senvaltioiden suostumuksella. Voiko komissio kertoa, eik(cid:246) sen mielest(cid:228) olisi parempi lyk(cid:228)t(cid:228) s(cid:228)(cid:228)d(cid:246)ksen hyv(cid:228)ksymist(cid:228) siihen asti, kunnes edell(cid:228) mainitut vaatimukset on tarkemmin tutkittu? (1) EYVL L 221, 12. 8. 1974, s. 10. Erkki Liikasen komission puolesta antama vastaus (25. tammikuuta 2000) Komissio on antanut vuonna 1996 direktiiviehdotuksen (1), jonka tarkoituksena on hunajaa koskevan j(cid:228)senvaltioiden lains(cid:228)(cid:228)d(cid:228)nn(cid:246)n yhdenmukaistamisesta 22 p(cid:228)iv(cid:228)n(cid:228) hein(cid:228)kuuta 1974 annetun neuvoston direktiivin 74/409/ETY (2) yksinkertaistaminen ja korvaaminen. Ehdotuksen valmistelussa ja siihen liitty- viss(cid:228) keskusteluissa komissio on ottanut huomioon (cid:129) Edinburghissa pidetyn Eurooppa-neuvoston kokouk- sen sille antaman valtuutuksen mukaisesti (cid:129) niiden kaikkien osapuolten yhteis(cid:246)n edut, joita asia koskee. Hunajaa koskevassa direktiiviehdotuksessa annetaan hunajan m(cid:228)(cid:228)ritelm(cid:228) ja tietyt koostumusta 1. koskevat kriteerit, jotka kaiken sek(cid:228) yhteis(cid:246)ss(cid:228) ett(cid:228) yhteis(cid:246)n ulkopuolella tuotetun hunajan on t(cid:228)ytett(cid:228)v(cid:228), jotta sit(cid:228) voidaan myyd(cid:228) t(cid:228)ll(cid:228) hunajan nimityksell(cid:228). Olisi sek(cid:228) yhteis(cid:246)n ett(cid:228) kansainv(cid:228)list(cid:228) kaupank(cid:228)ynti(cid:228) ohjaavien s(cid:228)(cid:228)nt(cid:246)jen vastaista kielt(cid:228)yty(cid:228) tuo- 2. masta hunajaa yhteis(cid:246)n ulkopuolelta, mik(cid:228)li se on direktiiviss(cid:228) annettujen hunajaa koskevien s(cid:228)(cid:228)nn(cid:246)sten mukaista. Komission on kuitenkin p(cid:228)(cid:228)tt(cid:228)nyt muuttaa ehdotustaan Euroopan parlamentin toukokuussa 1999 antaman lausunnon perusteella siten, ett(cid:228) hunajan alkuper(cid:228)n ilmaiseva pakkausmerkint(cid:228) on pakolli- nen silloin, kun hunaja on per(cid:228)isin yhteis(cid:246)n ulkopuolelta. Neuvoston kokouksissa jotkut j(cid:228)senvaltiot ovat ottaneet esille yhteis(cid:246)st(cid:228) ja yhteis(cid:246)n ulkopuolelta per(cid:228)isin olevien hunajasekoitusten tuotemerkinn(cid:228)t. T(cid:228)m(cid:228) asia on kuitenkin viel(cid:228) auki. (1) (2) EYVL C 378, 13. 12. 1996. EYVL L 221, 12. 8. 1974. (2000/C 225 E/142) KIRJALLINEN KYSYMYS E-2428/99 esitt(cid:228)j(cid:228)(t): Piia-Noora Kauppi (PPE-DE) komissiolle (16. joulukuuta 1999) Aihe: Kilpa- ja harrastusk(cid:228)yt(cid:246)ss(cid:228) olevien hevosten sulkeminen el(cid:228)inl(cid:228)(cid:228)kint(cid:228)s(cid:228)(cid:228)nn(cid:246)sten ulkopuolelle Hevonen luokitellaan unionissa tuotantoel(cid:228)imeksi, jolle ei saa antaa tiettyj(cid:228) l(cid:228)(cid:228)kkeit(cid:228) lihan laadun vuoksi. Viimeaikaiset ruokaskandaalit ovatkin saaneet viranomaiset varpailleen ja l(cid:228)(cid:228)kint(cid:228)s(cid:228)(cid:228)nn(cid:246)ksi(cid:228) on noudatet- tava, vaikkei el(cid:228)imen liha k(cid:228)yt(cid:228)nn(cid:246)ss(cid:228) ihmisten elintarvikkeiksi p(cid:228)(cid:228)tyisik(cid:228)(cid:228)n. C 225 E/132 Euroopan yhteis(cid:246)jen virallinen lehti FI 8. 8. 2000 Suomalainen hevonen on l(cid:228)hinn(cid:228) kilpa- ja harrastusel(cid:228)in. Vain alle puolet hevosista teurastetaan ja n(cid:228)ist(cid:228)kin hevosista vain murto-osaa k(cid:228)ytet(cid:228)(cid:228)n elintarviketeollisuudessa. Siksi olisikin todella t(cid:228)rke(cid:228)(cid:228), ett(cid:228) kilpa- ja harrastusk(cid:228)yt(cid:246)ss(cid:228) olevat hevoset j(cid:228)tett(cid:228)isiin l(cid:228)(cid:228)kint(cid:228)s(cid:228)(cid:228)nn(cid:246)sten ulkopuolelle. Komissio on ilmeisesti kanssani samaa mielt(cid:228) ja se on tehnyt asiasta ehdotuksen neuvostolle. Asia tuntuu t(cid:228)st(cid:228) huolimatta viipyv(cid:228)n, joten kysyn: 1. Miss(cid:228) aikataulussa komissio aikoo edet(cid:228) siin(cid:228), ett(cid:228) kilpa- ja harrastehevoset erotetaan tuotantoe- l(cid:228)imiksi luokitelluista hevosista? 2. Mik(cid:228)li komission esitykset asian suhteen viipyv(cid:228)t, miten kilpa- ja harrastehevosia t(cid:228)ll(cid:228) hetkell(cid:228) voidaan l(cid:228)(cid:228)kit(cid:228), kun tarvittaville l(cid:228)(cid:228)kkeille ei viel(cid:228) ole m(cid:228)(cid:228)ritelty maksimij(cid:228)(cid:228)m(cid:228)raja-arvoja (MRL-arvoja)? Erkki Liikasen komission puolesta antama vastaus (28. tammikuuta 2000) Pysyv(cid:228)n kotiel(cid:228)injalostusta k(cid:228)sittelev(cid:228)n komitean ja pysyv(cid:228)n el(cid:228)inl(cid:228)(cid:228)kint(cid:228)komitean muodostama sekakomi- tea antoi 8. 12. 1999 pidetyss(cid:228) kokouksessaan m(cid:228)(cid:228)r(cid:228)enemmist(cid:246)ll(cid:228) my(cid:246)nteisen lausunnon, jonka j(cid:228)lkeen komissio teki p(cid:228)(cid:228)t(cid:246)ksen (1) jalostukseen ja tuotantoon tarkoitettujen rekister(cid:246)ityjen hevosel(cid:228)inten mukana seuraavasta tunnistusasiakirjasta (passista). P(cid:228)(cid:228)t(cid:246)s perustui el(cid:228)inten terveytt(cid:228) koskevista vaatimuksista el(cid:228)vien hevosel(cid:228)inten liikkuvuuden ja kolmansista maista tapahtuvan tuonnin osalta 26 p(cid:228)iv(cid:228)n(cid:228) kes(cid:228)kuuta 1990 annettuun neuvoston direktiiviin 90/426/ETY (2) ja jalostusta ja polveutumista koskevista edellytyk- sist(cid:228) yhteis(cid:246)n sis(cid:228)isess(cid:228) hevosel(cid:228)inten kaupassa 26 p(cid:228)iv(cid:228)n(cid:228) kes(cid:228)kuuta 1990 annettuun neuvoston direktii- viin 90/427/ETY (2). Jalostukseen ja tuotantoon tarkoitettujen hevosel(cid:228)inten mukana seuraavassa tunnistusasiakirjassa k(cid:228)ytet(cid:228)(cid:228)n osittain samoja tietoja kuin p(cid:228)(cid:228)t(cid:246)ksell(cid:228) 93/623/ETY (3) perustetussa, kansainv(cid:228)lisesti tunnustetussa rekiste- r(cid:246)ityjen hevosel(cid:228)inten tunnistusasiakirjassa. Rekister(cid:246)ityjen hevosel(cid:228)inten sek(cid:228) jalostukseen ja tuotantoon tarkoitettujen hevosel(cid:228)inten mukana seuraavaan tunnistusasiakirjaan lis(cid:228)t(cid:228)(cid:228)n erityinen luku, johon merki- t(cid:228)(cid:228)n, ett(cid:228) hevosel(cid:228)in ei ole tarkoitettu teurastettavaksi ihmisravinnoksi tai ett(cid:228) hevosel(cid:228)in on tarkoitettu teurastettavaksi sill(cid:228) ehdolla, ett(cid:228) jos el(cid:228)int(cid:228) hoidetaan yhteis(cid:246)n menettelyst(cid:228) el(cid:228)inl(cid:228)(cid:228)kej(cid:228)(cid:228)mien enimm(cid:228)is- m(cid:228)(cid:228)rien vahvistamiseksi el(cid:228)inper(cid:228)isiss(cid:228) elintarvikkeissa 26 p(cid:228)iv(cid:228)n(cid:228) kes(cid:228)kuuta 1990 annetun neuvoston asetuksen (ETY) N:o 2377/90 (4) III kuulumattomia aineita sis(cid:228)lt(cid:228)vill(cid:228) l(cid:228)(cid:228)kkeill(cid:228), tai l(cid:228)(cid:228)kehoito on ilmoitettava ja on noudatettava 6 kuukauden yleist(cid:228) varoaikaa. liitteeseen I, II Yhteis(cid:246)ss(cid:228) kiellet(cid:228)(cid:228)n 1. 1. 2000 alkaen sellaisten farmakologisesti vaikuttavien aineiden k(cid:228)ytt(cid:228)minen elin- tarvikkeita tuottavien el(cid:228)inten l(cid:228)(cid:228)kkeen(cid:228), jotka eiv(cid:228)t sis(cid:228)lly asetuksen (ETY) N:o 2377/90 liitteeseen I, II tai III. Siksi n(cid:228)ihin liitteisiin sis(cid:228)ltym(cid:228)tt(cid:246)mi(cid:228) aineita voidaan antaa tai m(cid:228)(cid:228)r(cid:228)t(cid:228) hevosel(cid:228)imelle vasta sen j(cid:228)lkeen, kun el(cid:228)inl(cid:228)(cid:228)k(cid:228)ri on varmistanut, ett(cid:228) hevosel(cid:228)in on asianmukaisesti merkitty tunnistusasiakirjan uuteen lukuun joko el(cid:228)imeksi, jota ei ole tarkoitettu teurastettavaksi, tai el(cid:228)imeksi, joka on tarkoitettu teurastetta- vaksi edell(cid:228) esitetyin edellytyksin. Kun hevosel(cid:228)imet tuodaan teurastamoon, teurastamon virkael(cid:228)inl(cid:228)(cid:228)k(cid:228)rin on tarkistettava tunnistusasiakirja jotta h(cid:228)n voi tunnistaa teurasel(cid:228)imen ja tarkistaa l(cid:228)(cid:228)kint(cid:228)tiedot ante mortem -tarkastuksen yhteydess(cid:228), varmistuakseen vaaditun varoajan p(cid:228)(cid:228)ttymisest(cid:228). (1) (2) (3) (4) (ei viel(cid:228) julkaistu). EYVL L 296, 27. 10. 1990. EYVL L 298, 3. 12. 1993. EYVL L 87, 2. 4. 1992. (2000/C 225 E/143) KIRJALLINEN KYSYMYS E-2431/99 esitt(cid:228)j(cid:228)(t): Roberta Angelilli (NI) komissiolle (16. joulukuuta 1999) Aihe: Tavoite 2 ja Lazion alue Viimeaikaiset alueellisia tavoitteita koskevat j(cid:228)rjestelyt ja n(cid:228)in ollen Euroopan unionin rakennerahastoista my(cid:246)nnett(cid:228)vien varojen ohjaaminen on tavoitteiden uudelleenm(cid:228)(cid:228)rittelemisen vuoksi aiheuttanut useita


title: WRITTEN QUESTION E-2433/99 by Ilda Figueiredo (GUE/NGL) to the Commission. Reform of the banana sector with reference to the WTO panel.

eurovoc_concepts:
ACP countries
Azores
Canary Islands
EU production
Madeira
World Trade Organisation
customs duties
economic consequence
fruit-growing
import (EU)
monetary compensatory amount
overseas department (France)
overseas territory
tropical fruit

text: 8. 8. 2000 EN Official Journal of the European Communities C 225 E/133 status. In particular, the proposal by the Lazio regional authorities regarding Objective 2 does not appear to reflect adequately the development characteristics of the various areas concerned and therefore does not correspond to the Commission(cid:146)s guidelines to the Member States in this connection. Can the Commission answer the following: 1. Has it already intervened regarding the definition of eligible areas in Lazio and if so, in what way? 2. Has it expressed itself in favour of the proposal by Lazio regarding the redefinition of Objective status, and in particular of Objective 2? Answer given by Mr Barnier on behalf of the Commission (21 January 2000) Following the Commission(cid:146)s decision of 1 July 1999 setting, for each Member State, the maximum population eligible for Objective 2 assistance in 2000-2006, the national authorities were invited to send the Commission (at the latest by 31 August 1999) their proposed list of eligible areas within their territory. The Italian authorities sent their proposal on 1 October 1999. On 11 October 1999, the Italian authorities were informed that their proposal was not acceptable as it did not comply with Article 4(4) of Council Regulation (EC) No 1260/1999 (1) of 21 June 1999, which the areas that satisfy the (cid:145)Community(cid:146) criteria laid down in Article 4(5) and (6) must contain at least 50 % of the population eligible for Objective 2 assistance. The Commission therefore called on the Italian authorities to draw up a new proposal in compliance with the Regulation. As soon as it receives the revised Italian proposal, the Commission will evaluate the eligibility of the Italian region of Lazio for Objective 2 assistance. (1) Council Regulation (EC) No 1260/1999 of 21 June 1999 laying down general provisions on the Structural Funds: OJ L 161, 26. 6. 1999. (2000/C 225 E/144) WRITTEN QUESTION E-2433/99 by Ilda Figueiredo (GUE/NGL) to the Commission (16 December 1999) Subject: Reform of the banana sector with reference to the WTO panel At the Council meeting of Agriculture Ministers on 15 November the Commission put forward a proposal for an amendment to the customs arrangements relating to the banana sector. The purpose of the proposal is to put an end to import quotas and to base the arrangements solely on customs duties with effect from 1 January 2006. This is an attempt to bring the banana regime into line with the WTO rules, in response to the criticisms expressed by the USA and the multinational companies which export from the (cid:145)dollar banana(cid:146) area. Has the Commission carried out any research into the impact which any change in the arrangements would have on Community producers, particularly in view of the fact that there is to be an automatic shift to a scheme based solely on customs duties (which could be reduced as a result of the WTO Millennium Round negotiations)? If such research has been carried out, what were the main findings thereof? If Community producers suffer any losses, what action is the Commission intending to take in order to compensate them and to provide support for the sector and its future? Has the Commission carried out any research into the impact which any change in the arrangements would have on ACP producers, particularly in view of the fact that there is to be an automatic shift to a scheme based solely on customs duties? What action does the Commission intend to propose in terms of cooperation policy and the Community budget in order to compensate ACP producers for their losses? C 225 E/134 Official Journal of the European Communities EN 8. 8. 2000 Answer given by Mr Fischler on behalf of the Commission (14 January 2000) The World Trade Organisation (WTO) panel decision did not call into question the Community aid scheme under Commission Regulation (EEC) No 1858/93 of 9 July 1993 laying down detailed rules for applying Council Regulation (EEC) No 404/93 as regards the aid scheme to compensate for loss of income from marketing in the banana sector (1). The Commission considers that support for Community producers is guaranteed by the current system of compensatory aid, under which the amount fixed for each marketing year corresponds to the difference between the flat-rate reference income (which was increased by 5 % in 1998 and up to 8 % from 1999) and the average prices obtained during the year in which the bananas were marketed. Through providing full compensation regardless of price trends on the Community market, the system thus ensures that Community production is sold. The mechanism(cid:146)s effectiveness was confirmed during 1999, when banana prices on the world market slumped and compensatory aid enabled all Community production to be sold and producers(cid:146) income to be maintained. The Commission takes the view that the compensatory aid scheme will absorb the impact, at production level, of the proposed changes. The financial statement presented with the Commission proposal estimated that its budgetary impact would be to increase expenditure by € 77 million and revenue by € 30 million. The budgetary impact of applying a system based solely on tariffs cannot be quantified at this stage. African, Caribbean and Pacific (ACP) producers are already covered by Council Regulation (EC) No 856/ 1999 of 22 April 1999 establishing a special framework of assistance for traditional ACP suppliers of bananas (2). The Commission will, in any event, assess whether this support (which has been proposed in the light of the previous changes to the common market organisation) will be sufficient to help traditional ACP suppliers retain their place in the Community market. (1) OJ L 170, 13. 7. 1993. (2) OJ L 108, 27. 4. 1999. (2000/C 225 E/145) WRITTEN QUESTION E-2437/99 by Claude Moraes (PSE) to the Commission (16 December 1999) Subject: Right of establishment in the EU for nationals of Central and Eastern Europe countries (CEECs) for the purposes of business or of providing services as self-employed persons 1. Has the Commission any knowledge of the number of nationals of Central and Eastern European countries (CEECs) who have sought permission to establish themselves in the EU in the last two years in accordance with the relevant provisions of the Agreements between the CEE and the EU? Has the Commission produced any guidance for nationals of Central and Eastern European countries 2. seeking to establish themselves in accordance with these provisions? Has the Commission produced any memoranda or advice notes for the national authorities of the 3. Central and Eastern European countries concerning the right of establishment under these Agreements? Has the Commission received any complaints from nationals of Central and Eastern European 4. countries with regard to the exercise of the right of establishment under these Agreements?


title: ΓΡΑΠΤΗ ΕΡΩΤΗΣΗ E-2485/99 υποβολή: Karin Riis-Jørgensen (ELDR) προς την Επιτροπή. Ενισχύσεις για τη διέλευση της σταθερής σύνδεσης στον πορθμό του Öresund.

eurovoc_concepts:
Denmark
Sweden
control of State aid
infringement of EU law
rail transport

text: C 374 E/4 Epi·shmh Efhmeri·da tvn Eyrvpai¤kv·n Koinoth·tvn EL 28. 12. 2000 (cid:211)son afora· eidiko·tera thn Portogali·a symplhrvmatiko· poso· 30 ekat. eyrv· xorhgh·uhke to 1993, sto plai·sio thw prvtoboyli·aw ayth·w• to poso· ayto· e·xei h·dh katablhuei· plh·rvw. Kata·logow tvn sxedi·vn poy xrhmatodotoy·ntai sthn Portogali·a sto plai·sio thw en lo·gv prvtoboyli·aw diabiba·sthke sto Ajio·timo Me·low toy Koinoboyli·oy kai sth Genikh· Grammatei·a toy Koinoboyli·oy. (2000/C 374 E/004) GRAPTH ERVTHSH E-2485/99 ypobolh·: Karin Riis-Jørgensen (ELDR) prow thn Epitroph· (16 Dekembri·oy 1999) Ue·ma: Enisxy·seiw gia th die·leysh thw stauerh·w sy·ndeshw ston porumo· toy Öresund Anaforika· me th ue·sh se leitoyrgi·a thw stauerh·w sy·ndeshw ston porumo· toy Fresund, zhtei·tai apo· thn Epitroph· na anafe·rei kata· po·son oi danike·w kai/h· soyhdike·w arxe·w e·xoyn koinopoih·sei oiadh·pote koinh· kratikh· eni·sxysh, antistoi·xvw, prow ton Organismo· Sidhrodro·mvn Soyhdi·aw kai ton Organismo· Sidhrodro·mvn Dani·aw, eni·sxysh h opoi·a e·xei vw sto·xo th mei·vsh tvn timv·n tvn sidhrodromikv·n eisithri·vn kata· e·na poso· poy antistoixei· sta shmerina· dio·dia gia th die·leysh thw ge·fyraw, pra·gma poy isodynamei· me epido·thsh leitoyrgi·aw toy e·rgoy. Ua mporoy·se epi·shw h Epitroph· na anafe·rei ea·n, kata· thn a·poch· thw, mia koinh· eunikh· eni·sxysh parexo·menh se e·nan euniko· organismo· sidhrodro·mvn gia thn ka·lych tvn telv·n die·leyshw miaw ge·fyraw nouey·ei ton antagvnismo· eiw ba·row tvn porumei·vn poy pragmatopoioy·n th matafora· epibatv·n dia uala·sshw ston porumo· toy Fresund; Uevrei· h Epitroph· o·ti h kata·stash ayth· ei·nai sy·mfvnh me tiw diata·jeiw thw Synuh·khw gia thn katanomh· tvn eunikv·n enisxy·sevn; Apa·nthsh thw kaw de Palacio ej ono·matow thw Epitroph·w (9 Febroyari·oy 2000) Stiw 30 Septembri·oy 1998 oi danike·w arxe·w koinopoi·hsan sthn Epitroph· sy·sthma kratikv·n enisxy·sevn sxetika· me periballontikh· epixorh·ghsh gia thn sidhrodromikh· metafora· emporeyma·tvn. H nomikh· ba·sh toy systh·matow ei·nai o daniko·w no·mow 289 thw 18hw Aprili·oy 1998 peri· uespi·sevw nomikoy· plaisi·oy gia tiw sidhrodromike·w metafore·w sthn Dani·a, o opoi·ow, metajy· a·llvn, perie·xei diata·jeiw gia thn plhrvmh· telv·n ypodomh·w gia thn xrh·sh thw sidhrodromikh·w ypodomh·w, kauv·w kai gia tiw epixorhgh·seiw se sidhrodromike·w epixeirh·seiw gia periballontikoy·w lo·goyw. Stiw 21 Aprili·oy 1999, h Epitroph· e·krine to koinopoihue·n sy·sthma enisxy·sevn symbato· me thn eniai·a agora·. Sthn apo·fash· thw, h Epitroph· synekti·mhse o·ti h epixorh·ghsh ei·nai shmantika· mikro·terh apo· to (cid:129) kat(cid:146) ekti·mhsin (cid:129) mh plhrvue·n ejvteriko· ko·stow tvn odikv·n metaforv·n, kai o·ti to sy·sthma enisxy·sevn ei·nai anoikto· se ka·ue epixei·rhsh poy metafe·rei emporey·mata sidhrodromikv·w, kauv·w kai o·ti apoklei·ei thn diametako·mish, prokeime·noy na prostatey·sei ta symfe·ronta tvn uala·ssivn metaforv·n, eno·w a·lloy, filikoy· prow to periba·llon, tro·poy metafora·w. Ka·ue euniko· me·tro poy apalla·ssei etairei·ew metaforv·n apo· thn (cid:129) oiasdh·pote morfh·w (cid:129) katabolh· telv·n mporei· na uevrhuei·, kat(cid:146) arxh·n, vw synisto·n stre·blvsh toy antagvnismoy· metajy· tro·pvn metafora·w kai dy·natai na eggrafei· stiw peri· kratikv·n enisxy·sevn diata·jeiw thw synuh·khw EK, ston baumo· poy ephrea·zei to empo·rio metajy· kratv·n melv·n. Eidiko·tera, oi kratike·w enisxy·seiw prow toyw sidhrodro·moyw dy·nantai na apotele·soyn stre·blvsh toy antagvnismoy· me ta ploi·a kai tana·palin, o·tan oi enisxy·seiw ayte·w xorhgoy·ntai se tmh·ma thw agora·w (se emporikh· odo·) o·poy o sidhro·dromow kai oi uala·ssiew metafore·w bri·skontai se antagvnistikh· ue·sh. Gia na ektimh·sei thn symbato·thta thw en lo·gv epixorh·ghshw me th synuh·kh EK, h Epitroph· pre·pei prv·ta na apotele·sei ton apode·kth de·oysaw koinopoi·hshw te·toivn me·trvn, sy·mfvna me to a·ruro 88 para·grafow 3 (prv·hn a·ruro 93) thw synuh·khw EK. Den ei·nai dynato·n na ypa·rjei en prokeime·nv kata·llhlh apa·nthsh xvri·w na e·xoyn sygkentrvuei· o·lew oi prow toy·to anagkai·ew plhrofori·ew


title: WRITTEN QUESTION E-2382/99 by Bart Staes (Verts/ALE) to the Commission. Impact on Southern Africa of the trade, development and cooperation agreement with South Africa.

eurovoc_concepts:
South Africa
Southern Africa
economic consequence
trade agreement (EU)

text: C 280 E/36 Official Journal of the European Communities EN 3. 10. 2000 EEC of 2 April 1979 on the conservation of wild birds (1), Article 6 (3) and (4) of Council Directive 92/43/ EEC of 21 May 1992 on the conservation of natural habitats and of wild flora and fauna (2) have to be applied. This means that all the specific requirements of those provisions have to be met. One of the requirements in Article 6 (4) is that a plan or project can only be carried out in the absence of alternative solutions. This requirement may lead to the adoption of an alternative route in stead of a re-opening of the Iron Rhine railway line. (1) OJ L 103, 25. 4. 1979. (2) OJ L 206, 22. 7. 1992. (2000/C 280 E/034) WRITTEN QUESTION E-2382/99 by Bart Staes (Verts/ALE) to the Commission (16 December 1999) Subject: Impact on Southern Africa of the trade, development and cooperation agreement with South Africa The trade, development and cooperation agreement between the European Union and the Republic of South Africa has recently been approved. It provides for free access to the South African market for 86 % of EU products, while the 15 EU Member States will grant free access to 95 % of South African products. Given that South Africa is a member of two regional pacts, this will also have an impact on other countries in the region. South Africa is in a customs union with Botswana, Namibia, Lesotho and Swaziland. These five countries are not allowed to levy tariffs at their common frontiers. Accordingly, EU products will be bought and sold (cid:129) via South Africa (cid:129) tariff-free, even though Botswana, Namibia, Lesotho and Swaziland are heavily dependent on customs tariffs for their revenue. In addition, South Africa is negotiating liberalisation of trade with the ten other members of the SADC. Until an agreement is reached, businesses in the SADC countries will find it harder than their EU competitors to gain access to the South African market. On 22 September 1998 Commissioner Pinheiro said in answer to written question E-2287/98 (1) by Mr Jaak Vandemeulebroucke that (cid:145)the Commission expects that the envisaged agreement will have a positive dynamic economic effect on both South Africa and the other countries in the region(cid:146). How much revenue did Botswana, Namibia, Lesotho and Swaziland derive from the collection of 1. customs duties in 1995, 1996, 1997, 1998 and 1999? 2. What is the estimated revenue from customs duty levied on EU products imported into Botswana, Namibia, Lesotho and Swaziland in 2000 and 2001? 3. What indicators suggest that the agreement will have (cid:145)a positive dynamic economic effect(cid:146) on Botswana, Namibia, Lesotho and Swaziland? 4. What indicators point to the agreement having (cid:145)a positive dynamic economic effect(cid:146) on the other SADC countries? (1) OJ C 118, 29. 4. 1999, p. 51. 3. 10. 2000 EN Official Journal of the European Communities C 280 E/37 Answer given by Mr Nielson on behalf of the Commission (25 January 2000) A detailed study, funded by the Commission, has been undertaken by the Botswana institute for development policy analysis (BIDPA) to assess the likely impact of the Community/Southern Africa (SA) free trade agreement (FTA) on the economies of Botswana, Lesotho, Namibia and Swaziland (BLNS) and to put forward recommendations which will enable BLNS states to maximise the expected benefits whilst also minimising any potential adverse effects. The average annual revenues (as a % of GDP) derived from the common revenue pool by the BLNS countries are: Botswana: 17,1 %, Lesotho: 41,7 %, Namibia: 27,6 % and Swaziland: 44,8 %. The estimated effects of the trade development and co-operation agreement (TDCA) (diminishing common revenue pool because of lower tariffs) on the total revenues of BLNS countries are: Botswana: (cid:141)5,3 %, Lesotho: (cid:141)12,9 %, Namibia: (cid:141)8,6 % and Swaziland (cid:141)13,9 %. In reality the loss of revenue should be far less because many sensitive products have been excluded from liberalisation on the SA side, and there is no reason to believe that there will be a lasting shortfall. The Community is ready to assist the BLNS countries in implementing fiscal reform, necessary to diversify their sources of income and needed independently from the TDCA. There will be gains for consumers and entrepreneurs alike. The business community will have access to a cheaper, better quality and more diversified range of supplies for their inputs and capital goods. They will thus stand better prospects for investing, exporting and hiring additional staff. Job creation and investment drive in the Southern African Customers Union (SACU) are expected to be the main positive effects of the FTA. This will result in a distributional gain within the BLNS economies and allow their ministries of finance to collect revenue through a different system of taxes. The relationship between SADC and the FTA is more difficult to deal with in practical terms, because SADC has yet to become a structured entity on the trade front, through the negotiation of its own FTA. The general Community policy, to encourage economic integration at a regional level, ensured that it did not gain a better access to the SA market than the SADC countries; for example SA reserved certain trade concessions in the textile sector to its SADC partners. Furthermore, any trade concessions obtained by the Community under the FTA with SA have to be extended, according to the SADC trade protocol, to all SADC members. This ensures that SADC countries will secure better access to the SA market. (2000/C 280 E/035) WRITTEN QUESTION E-2384/99 by Bart Staes (Verts/ALE) to the Commission (16 December 1999) Subject: Shutdown of the unsafe nuclear reactor in Bohunice (Slovakia) The Commission originally said that Slovakia(cid:146)s accession to the European Union depended on the extremely unsafe nuclear reactor in Bohunice being shut down by next year. However, in mid-October the Commission said it would be satisfied with a shutdown in the period 2006-2008. Considerable opposition has been prompted by this decision. 1. Why has the Commission gone back on its original position that the extremely unsafe reactor should be shut down next year? Does the Commission feel that shutting down the extremely unsafe reactor is no longer a prior 2. condition for accession? If so, why does it consider that the shutdown is no longer necessary?


title: QUESTION ÉCRITE E-2485/99 posée par Karin Riis-Jørgensen (ELDR) à la Commission. Aides au profit de la liaison fixe au travers du détroit d'Öresund.

text: C 374 E/4 Journal officiel des CommunautØs europØennes FR 28. 12. 2000 En ce qui concerne plus particuliŁrement le Portugal, un montant additionnel de 30 millions d(cid:146)euros a ØtØ accordØ en 1993, au titre de cette initiative; ce montant a dØj(cid:224) ØtØ payØ entiŁrement. La liste des projets financØs au Portugal au titre de ladite initiative est transmise (cid:224) l(cid:146)Honorable Parlemen- taire et au SecrØtariat gØnØral du Parlement. (2000/C 374 E/004) QUESTION (cid:201)CRITE E-2485/99 posØe par Karin Riis-Jłrgensen (ELDR) (cid:224) la Commission (16 dØcembre 1999) Objet: Aides au profit de la liaison fixe au travers du dØtroit d(cid:146)(cid:214)resund S(cid:146)agissant de la mise en service de la liaison fixe au travers du dØtroit d(cid:146)(cid:214)resund, la Commission pourrait- elle indiquer dans quelle mesure les autoritØs danoises et/ou suØdoises ont donnØ notification d(cid:146)une aide nationale partagØe entre la SociØtØ suØdoise des chemins de fer et les Chemins de fer danois, de nature (cid:224) rØduire les tarifs ferroviaires d(cid:146)un montant correspondant au pØage effectif acquittØ au passage du pont, d(cid:146)oø un subventionnement en faveur de l(cid:146)exploitation de l(cid:146)ouvrage. La Commission pourait-elle par ailleurs indiquer si, selon elle, une aide nationale, octroyØe (cid:224) une sociØtØ nationale de chemins de fer, au titre de la couverture des droits de pØage affØrents (cid:224) un pont fausse la concurrence au dØtriment des transbordeurs assurant la liaison maritime au travers du dØtroit d(cid:146)(cid:214)resund? La Commission juge-t-elle semblable situation en conformitØ aux dispositions du traitØ realtives (cid:224) la rØpartition des aides nationales? RØponse de Mme de Palacio au nom de la Commission (9 fØvrier 2000) Le 30 septembre 1998, les autoritØs danoises ont notifiØ (cid:224) la Commission un rØgime d(cid:146)aides d(cid:146)Øtat concernant une subvention environnementale en faveur du transport ferroviaire des marchandises. La base juridique de ce rØgime est la loi danoise no 289 du 18 mai 1998 qui fixe un cadre juridique pour l(cid:146)exploitation des chemins de fer au Danemark et contient, entre autres, des mesures sur le paiement des dØpenses d(cid:146)infrastructure pour l(cid:146)utilisation des infrastructures ferroviaires et l(cid:146)octroi de subventions aux opØrations ferroviaires pour des motifs environnementaux. Le 21 avril 1999, la Commission a estimØ que le rØgime d(cid:146)aide notifiØ Øtait compatible avec le marchØ commun. Dans sa dØcision, la Commission a tenu compte du fait que les subventions Øtaient nettemement infØrieures aux estimations des coßts externes non payØs des transports routiers, que le rØgime d(cid:146)aide est ouvert (cid:224) toute entreprise transportant des marchandises par chemin de fer et qu(cid:146)il exclut le trafic de transit afin de sauvegarder les intØrŒts du transport maritime, un autre mode de transport respectueux de l(cid:146)environnement. Toute mesure nationale dispensant les sociØtØs de transport de toute forme de charges peut en principe fausser la concurrence entre les modes de transport et entrer dans le champ d(cid:146)application des rŁgles d(cid:146)aides d(cid:146)Øtat du traitØ CE dans la mesure oø cela affecte le commerce entre les (cid:201)tats membres. Plus prØcisØment, un soutien Øtatique en faveur des chemins de fer peut fausser la concurrence avec les navires et vice-versa, lorsque ce soutien est accordØ (cid:224) un segment de marchØ (une voie) oø les chemins de fer et la navigation se font concurrence. Afin d(cid:146)Øvaluer la compatibilitØ de ces subventions avec le traitØ CE, il faut dßment notifier (cid:224) la Commission ces mesures conformØment (cid:224) l(cid:146)article 88, paragraphe 3, (ex article 93) du traitØ CE. Cependant, il n(cid:146)est pas possible de donner une rØponse adØquate (cid:224) cette question sans obtenir prØalablement toutes les informations nØcessaires (cid:224) une telle Øvaluation


title: ΓΡΑΠΤΗ ΕΡΩΤΗΣΗ E-2436/99 υποβολή: Diana Wallis (ELDR) προς την Επιτροπή. Οδηγία περί προστασίας των δεδομένων.

eurovoc_concepts: action for failure to fulfil an obligation

text: 1. 8. 2000 EL Epi·shmh Efhmeri·da tvn Eyrvpai¤kv·n Koinoth·tvn C 219 E/161 Eja·lloy, to Symboy·lio Genikv·n Ypoue·sevn, aphy·uyne epaneilhmme·new ekklh·seiw gia entatikopoi·hsh tvn pro- spaueiv·n, ek me·royw tvn Kosoba·rvn kai thw dieunoy·w paroysi·aw, me skopo· thn katapole·mhsh toy organvme·noy egklh·matow sto Kossyfope·dio. Sth syna·rthsh ayth·, to Symboy·lio, sth sy·nodo· toy stiw 6 Dekembri·oy, eje·frase thn ikanopoi·hsh· toy gia thn pro·uesh thw Epitroph·w na symperila·bei thn katapole·mhsh toy organvme·noy egklh·matow ston programmatismo· thw boh·ueiaw prow to Kossyfope·dio kata· to 2000 kai ka·lese ta kra·th me·lh na prosdiori·soyn thn kata·llhlh boh·ueia s(cid:146) ayto·n ton tome·a. (2000/C 219 E/204) GRAPTH ERVTHSH E-2432/99 ypobolh·: Michl Ebner (PPE-DE) prow thn Epitroph· (16 Dekembri·oy 1999) Ue·ma: Epanegkata·stash sto fysiko· periba·llon toy ly·koy, thw arkoy·daw kai toy ly·gka Mporei· na anafe·rei h Epitroph· an sh·mera sthn (cid:201)nvsh ektyli·ssontai sygkekrime·new dra·seiw (sygxrhmatodo- toy·menew h· mh ) gia thn epanegkata·stash sto fysiko· periba·llon toy ly·koy, thw arkoy·daw kai toy ly·gka, an kata· to pareluo·n xrhmatodoth·uhkan h· sygxrhmatodoth·uhkan prvtoboyli·ew ston tome·a ayto· kai an sto prosexe·w me·llon ua lhfuoy·n eidika· me·tra prow to skopo· ayto·; Apa·nthsh thw kaw Wallström ej ono·matow thw Epitroph·w (11 Ianoyari·oy 2000) (cid:201)xoyn xrhmatodothuei·, apo· to xrhmatodotiko· me·so LIFE-Nature kai ta prohgoy·mena· toy, apo· to 1988, polla· e·rga poy aposkopoy·n, ei·te a·mesa, ei·te e·mmesa, sth diath·rhsh toy ly·koy, thw kafetia·w arkoy·daw kai toy ly·gka. Eidiko·tera, 21 e·rga aforoy·san, metajy· a·llvn eidv·n, ton ly·ko, 14 ton ly·gka kai 17 thn kafetia· arkoy·da. Ta en lo·gv e·rga asfalv·w antiprosvpey·oyn th shmantiko·terh epe·ndysh thw Koino·thtaw gia thn prostasi·a aytv·n tvn eidv·n. Pe·ran aytv·n, ta kra·th me·lh mporei· na e·xoyn anala·bei paro·moiew h· symplhrvmatike·w prvtoboyli·ew sto plai·sio a·llvn koinotikv·n kondyli·vn. Mporei· na xrhmatodothuoy·n sto me·llon, sto plai·sio toy LIFE III, kai a·lla e·rga gia th diath·rhsh aytv·n tvn eidv·n, ypo· thn proy¤ po·uesh o·ti ua ypoblhuoy·n sxe·dia kalh·w poio·thtaw gia ton skopo· ayto·n. (2000/C 219 E/205) GRAPTH ERVTHSH E-2436/99 ypobolh·: Diana Wallis (ELDR) prow thn Epitroph· (16 Dekembri·oy 1999) Ue·ma: Odhgi·a peri· prostasi·aw tvn dedome·nvn Gnvri·zei h Epitroph· o·ti, lo·gv tvn diaforetikv·n proseggi·sevn poy e·xoyn yiouethuei·, se euniko· epi·pedo, vw prow thn efarmogh· thw odhgi·aw thw EE toy 1995 gia thn prostasi·a tvn dedome·nvn, oi eunikoi· no·moi peri· prostasi·aw tvn dedome·nvn synepa·gontai diakri·seiw eiw ba·row toy diameuoriakoy· empori·oy, pra·gma poy ua e·xei shmantikh· arnhtikh· epi·drash sthn ana·ptyjh toy hlektronikoy· empori·oy ento·w thw EE; (cid:201)na sxetiko· para·deigma ei·nai h epe·ktash toy pedi·oy efarmogh·w tvn no·mvn peri· prostasi·aw tvn dedome·nvn oy·tvw v·ste na kaly·ptontai o·xi mo·non ta prosvpika· dedome·na, o·pvw proe·blepe h odhgi·a, alla· kai h epejergasi·a tvn dedome·nvn poy aforoy·n epixeirh·seiw. Skopey·ei h Epitroph· na probei· se ene·rgeiew oy·tvw v·ste na periorisuei· h bla·bh poy prokalei· sthn arxh· thw esvterikh·w agora·w o yperboliko·w «kallvpismo·w» thw odhgi·aw kata· th metafora· thw sto euniko· di·kaio tvn kratv·n melv·n; C 219 E/162 Epi·shmh Efhmeri·da tvn Eyrvpai¤kv·n Koinoth·tvn EL 1. 8. 2000 Apa·nthsh toy k. Bolkestein ej ono·matow thw Epitroph·w (28 Ianoyari·oy 2000) H Epitroph· ektima· o·ti h odhgi·a 95/46/EK thw 24hw Oktvbri·oy 1995 sxetika· me thn prostasi·a tvn fysikv·n prosv·pvn e·nanti thw epejergasi·aw dedome·nvn prosvpikoy· xarakth·ra gia thn eley·uerh kyklofori·a tvn dedome·nvn aytv·n (1) sthn opoi·a anafe·retai to ajio·timo me·low,ei·nai e·na shmantiko· stoixei·o gia thn ana·ptyjh toy hlektronikoy· empori·oy. H odhgi·a ayth· e·xei sto·xo, pra·gmati, na epitrapei· h eley·uerh kyklofori·a tvn dedome·nvn prosvpikoy· xarakth·ra metajy· tvn kratv·n melv·n, eggyo·menh se o·lh thn Koino·thta e·na ychlo· epi·pedo prostasi·aw tvn uemelivdv·n dikaivma·tvn tvn prosv·pvn, eidika· toy dikaiv·matow idivtikh·w zvh·w. To epi·pedo ayto· prostasi·aw ei·nai aparai·thto gia thn ejasfa·lish empistosy·nhw tvn katanalvtv·n sth xrhsimopoi·hsh tvn parexome·nvn yphresiv·n kai, vw ek toy·toy, na epitrapei· h ana·ptyjh toy hlektronikoy· empori·oy. Gia toyw lo·goyw aytoy·w, h Epitroph· parakoloyuei· me idiai·tero endiafe·ron thn ensvma·tvsh thw odhgi·aw stiw eunike·w nomouesi·ew. H ensvma·tvsh ayth· den e·xei ako·mh peratvuei· se orisme·no ariumo· kratv·n, e·nanti tvn opoi·vn, h Epitroph· proe·bh, eja·lloy, se ene·rgeia gia para·bash tvn koinotikv·n ypoxrev·sevn. Sth shmerinh· fa·sh, h Epitroph· den diaue·tei plhrofori·ew poy na epibebaiv·noyn tiw aniso·thtew stiw opoi·ew anafe·retai to ajio·timo me·low. Paro·moiew aniso·thtew ei·nai dynato·n, anti·ueta, na proky·coyn apo· mi·a e·lleich ensvma·tvshw thw odhgi·aw. Ea·n proky·cei o·ti ta periuv·ria eligmv·n poy e·xoyn douei· sta kra·th me·lh me thn odhgi·a, eidika· o·son afora· thn epe·ktash thw prostasi·aw tvn dedome·nvn tvn nomikv·n prosv·pvn o·poy anafe·ruhke to ajio·timo me·low, ua h·tan dynato·n na dhmioyrgh·soyn empo·dia sthn svsth· leitoyrgi·a thw esvterikh·w agora·w, h Epitroph· den ua pare·leipe na bga·lei ta aparai·thta sympera·smata. (1) EE L 281 thw 23. 11. 1999. (2000/C 219 E/206) GRAPTH ERVTHSH P-2438/99 ypobolh·: W. G. van Velzen (PPE-DE) prow thn Epitroph· (13 Dekembri·oy 1999) Ue·ma: Syne·peiew thw apo·rrichw toy gallikoy· nomosxedi·oy peri· hlektrikoy· rey·matow gia thn esvterikh· agora· Env· h Gallikh· Eunosyne·leysh ene·krine se prv·th ana·gnvsh to nomosxe·dio peri· hlektrikoy· rey·matow stiw 2 Marti·oy e. e, h gallikh· Geroysi·a ape·rrice to en lo·gv nomosxe·dio stiw 18 Noembri·oy e. e. Epish·mvw, h eyrvpai¤kh· odhgi·a peri· hlektrismoy· e·prepe na metaferuei· sthn eunikh· nomouesi·a to argo·tero stiw 18 Febroyari·oy. Ypenuymi·zontaw thn apa·nthsh thw Epitroph·w se palaio·terew ervth·seiw toy ypogra·fontow genna·tai to 1. erv·thma poie·w syne·peiew e·xei, kata· th gnv·mh thw Epitroph·w, h apo·rrich toy gallikoy· nomosxedi·oy peri· hlektrismoy· gia thn eleyue·rvsh thw eyrvpai¤kh·w anti·stoixhw agora·w. H apo·rrich toy en lo·gv nomosxedi·oy sth Galli·a ua prokale·sei diata·rajh thw esvterikh·w agora·w 2. hlektrikoy· rey·matow sthn Eyrvpai¤kh· (cid:201)nvsh. xontaw afeno·w ypo·ch to gegono·w o·ti h eyrvpai¤kh· odhgi·a e·prepe na ei·xe metaferuei· sthn eunikh· nomouesi·a to argo·tero stiw 18 Febroyari·oy kai o·ti, afete·roy, h Galli·a ei·nai to monadiko· kra·tow me·low thw EE poy den e·xei ako·ma ekplhrv·sei th de·smeysh ayth·, fai·netai pro·sforo na kinhuei· h EE dikastikv·w kata· thw Galli·aw. Vsto·so, braxyproue·smvw, mi·a te·toia ki·nhsh, poy ei·nai kai xronobo·ra, den prosfe·rei anakoy·fish. Poie·w dra·seiw ei·nai diateueime·nh na anala·bei h Eyrvpai¤kh· Epitroph·, braxyproue·smvw, gia na prola·bei th stre·blvsh thw esvterikh·w agora·w hlektrikoy· rey·matow; (cid:201)xei enhmervuei· h Epitroph· apo· th gallikh· kybe·rnhsh sxetika· me to ue·ma kai sxetika· me ton tro·po poy h 3. gallikh· kybe·rnhsh sxedia·zei na apotre·cei, to syntomo·tero dynato·, e·na fragmo· thw esvterikh·w agora·w, kauv·w kai poia· sygkekrime·na me·tra epiuymei· na la·bei, kato·pin diaboyley·sevn me thn Epitroph·, gia na periori·sei sto ela·xisto dynato· th stre·blvsh thw esvterikh·w agora·w;


title: Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products

eurovoc_concepts:
European Medicines Agency
disease prevention
drugs classification
market approval
medical diagnosis
medicinal product
scientific research

text: 22. 1. 2000 EN Official Journal of the European Communities L 18/1 I (Acts whose publication is obligatory) REGULATION (EC) No 141/2000 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 1999 on orphan medicinal products THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, tions of competition and barriers to intra-Community trade; (4) (5) (6) (7) Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof, Having regard to the proposal from the Commission (1), Having regard to the opinion of the Economic and Social Committee (2), Acting in accordance with the procedure laid down in Article 251 of the Treaty (3), Whereas: (1) (2) (3) to diagnose, prevent or treat some conditions occur so infrequently that the cost of developing and bringing to the market a medicinal product the condition would not be recovered by the expected sales of the medicinal product; the pharmaceutical industry would be unwilling to develop the medicinal product under normal market conditions; these medicinal products are called ‘orphan’; patients suffering from rare conditions should be enti- tled to the same quality of treatment as other patients; it is therefore necessary to stimulate the research, develop- ment and bringing to the market of appropriate medica- tions by the pharmaceutical industry; incentives for the development of orphan medicinal products have been available in the United States of America since 1983 and in Japan since 1993; in the European Union, only limited action has been taken so far, whether at national or at Community level, to stimulate the development of orphan medicinal prod- ucts; such action is best taken at Community level in order to take advantage of the widest possible market and to avoid the dispersion of limited resources; action at Community level is preferable to uncoordinated meas- ures by the Member States which may result in distor- (1) OJ C 276, 4. 9. 1998, p. 7. (2) OJ C 101, 12. 4. 1999, p. 37. (3) Opinion of the European Parliament of 9 March 1999 (OJ C 175, 21. 6. 1999, p. 61), Council Common Position of 27 September 1999 (OJ C 317, 4. 11. 1999, p. 34) and Decision of the European Parliament of 15 December 1999 (not yet published in the Official Journal). orphan medicinal products eligible for incentives should be easily and unequivocally identified; it seems most appropriate to achieve this result through the establish- ment of an open and transparent Community procedure for the designation of potential medicinal products as orphan medicinal products; objective criteria for designation should be established; those criteria should be based on the prevalence of the condition for which diagnosis, prevention or treatment is sought; a prevalence of not more than five affected persons per 10 thousand is generally regarded as the appropriate threshold; medicinal products intended for a life-threatening, seriously debilitating or serious and chronic condition should be eligible even when the prevalence is higher than five per 10 thousand; for designation; a Committee composed of experts appointed by the Member States should be established to examine applica- tions this Committee should also include three representatives of patients' associations, designated by the Commission, and three other persons, also designated by the Commission, on a recommenda- tion from the European Agency for the Evaluation of Medicinal Products ‘the (hereinafter Agency’); the Agency should be responsible for the adequate coordination between the Committee on orphan medicinal products and the Committee on proprietary medicinal products; referred to as patients with such conditions deserve the same quality, safety and efficacy in medicinal products as other patients; orphan medicinal products should therefore be submitted to the normal evaluation process; sponsors of orphan medicinal products should have the possibility in order to of obtaining a Community authorisation; facilitate a Community authorisation, fees to be paid to the Agency should be waived at least in part; the Community budget should compensate the Agency for the loss in revenue thus occasioned; the maintenance of the granting or L 18/2 EN Official Journal of the European Communities 22. 1. 2000 (8) (9) (10) (11) experience in the United States of America and Japan shows that the strongest incentive for industry to invest in the development and marketing of orphan medicinal products is where there is a prospect of obtaining market exclusivity for a certain number of years during which part of the investment might be recovered; data protection under Article 4(8)(a)(iii) of Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or adminis- trative action relating to medicinal products (1) is not a incentive for that purpose; Member States sufficient acting independently cannot introduce such a measure without a Community dimension as such a provision would be contradictory to Directive 65/65/EEC; if such measures were adopted in an uncoordinated manner by the Member States, this would create obstacles to intra- Community trade, leading to distortions of competition and running counter to the single market; market exclu- sivity should however be limited to the therapeutic indi- cation for which orphan medicinal product designation has been obtained, without prejudice to existing intellec- tual property rights; the market exclusivity granted to an orphan medicinal product should not prevent the marketing of a similar medicinal product which could be of significant benefit to those affected by the condition; in the interest of patients, sponsors of orphan medicinal products designated under this Regulation should be entitled to the full benefit of any incentives granted by the Community or by the Member States to support the research and development of medicinal products for the diagnosis, prevention or including rare diseases; treatment of such conditions, the specific programme Biomed 2, of the fourth frame- work programme for research and technological devel- opment (1994 to 1998), supported research on the treatment of rare diseases, including methodologies for rapid schemes for the development of orphan medicinal products and inventories of available orphan medicinal products in Europe; those grants were intended to promote the establishment of cross national cooperation in order to implement basic and clinical research on rare diseases; research on rare diseases continues to be a priority for the Community, as it has been included in the fifth framework programme for research and techno- logical development (1998 to 2002); this Regulation establishes a legal framework which will allow the swift and effective implementation of the outcome of this research; rare diseases have been identified as a priority area for Community action within the framework for action in in its the field of public health; communication of concerning Community action on rare diseases within the frame- work for action in the field of public health has decided to give rare diseases priority within the public health the Commission, programme a framework; the European Parliament and the Council have adopted Decision No 1295/1999/EC of 29 April 1999 adopting a programme of Community action on rare diseases within the framework for action in the field of public health (1999 to 2003) (2), including actions to rare provide information, diseases in a population and to support relevant patient organisations; this Regulation implements one of the priorities laid down in this programme of action, to deal with clusters of HAVE ADOPTED THIS REGULATION: Article 1 Purpose The purpose of this Regulation is to lay down a Community procedure for the designation of medicinal products as orphan medicinal products and to provide incentives for the research, development and placing on the market of designated orphan medicinal products. Article 2 Definitions For the purposes of this Regulation: (a) ‘medicinal product’ means a medicinal product for human use, as defined in Article 2 of Directive 65/65/EEC; (b) ‘orphan medicinal product’ means a medicinal product designated as such under the terms and conditions of this Regulation; (c) ‘sponsor’ means any legal or natural person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product; (d) ‘Agency’ means the European Agency for the Evaluation of Medicinal Products. Article 3 Criteria for designation A medicinal product shall be designated as an orphan 1. medicinal product if its sponsor can establish: (a) that it is intended for the diagnosis, prevention or treat- ment of a life-threatening or chronically debilitating condi- tion affecting not more than five in 10 thousand persons in the Community when the application is made, or that it is intended for the diagnosis, prevention or treat- ment of a life-threatening, seriously debilitating or serious and chronic condition in the Community and that without incentives it is unlikely that the marketing of the medicinal product in the Community would generate sufficient return to justify the necessary investment; (1) OJ 22, 9. 2. 1965, p. 369. Directive as last amended by Directive 93/39/EEC (OJ L 214, 24. 8. 1993, p. 22). (2) OJ L 155, 22. 6. 1999, p. 1. 22. 1. 2000 EN Official Journal of the European Communities L 18/3 and (b) that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorised in the Community or, if such method exists, that the medicinal product will be of significant benefit to those affected by that condition. 2. The Commission shall adopt the necessary provisions for implementing this Article in the form of an implementing Regulation in accordance with the procedure laid down in Article 72 of Council Regulation (EEC) No 2309/93 (1). Article 4 Committee for Orphan Medicinal Products A Committee for Orphan Medicinal Products, hereinafter is hereby set up within the 1. referred to as ‘the Committee’, Agency. 2. The task of the Committee shall be: (a) to examine any application for the designation of a medi- cinal product as an orphan medicinal product which is submitted to it in accordance with this Regulation; (b) to advise the Commission on the establishment and devel- opment of a policy on orphan medicinal products for the European Union; (c) to assist the Commission in liaising internationally on matters relating to orphan medicinal products, and in liaising with patient support groups; (d) to assist the Commission in drawing up detailed guidelines. The Committee shall consist of one member nominated 3. by each Member State, three members nominated by the Commission to represent patients' organisations and three members nominated by the Commission on the basis of a recommendation from the Agency. The members of the Committee shall be appointed for a term of three years, which shall be renewable. They may be accompanied by experts. The Committee shall elect its Chairman for a term of 4. three years, renewable once. 5. The representatives of the Commission and the Executive Director of the Agency or his representative may attend all meetings of the Committee. The Agency 6. Committee. shall provide the secretariat of the 7. Members of the Committee shall be required, even after their duties have ceased, not to disclose any information of the kind covered by the obligation of professional secrecy. Article 5 Procedure for designation and removal from the register In order to obtain the designation of a medicinal product 1. as an orphan medicinal product, the sponsor shall submit an application to the Agency at any stage of the development of (1) OJ L 214, 24. 8. 1993, p. 1. Regulation as amended by Commission Regulation (EC) No 649/98 (OJ L 88, 24. 3. 1998, p. 7). the medicinal product before the application for marketing authorisation is made. The application shall be accompanied by the following 2. particulars and documents: (a) name or corporate name and permanent address of the sponsor; (b) active ingredients of the medicinal product; (c) proposed therapeutic indication; (d) justification that the criteria laid down in Article 3(1) are the stage of development, met and a description of including the indications expected. 3. The Commission shall, in consultation with the Member States, the Agency and interested parties, draw up detailed guidelines on the required format and content of applications for designation. 4. The Agency shall verify the validity of the application and prepare a summary report to the Committee. Where appro- priate, it may request the sponsor to supplement the particulars and documents accompanying the application. 5. The Agency shall ensure that an opinion is given by the Committee within 90 days of the receipt of a valid application. 6. When preparing its opinion, the Committee shall use its best endeavours to reach a consensus. If such a consensus cannot be reached, the opinion shall be adopted by a majority of two-thirds of the members of the Committee. The opinion may be obtained by written procedure. 7. Where the opinion of the Committee is that the applica- tion does not satisfy the criteria set out in Article 3(1), the Agency shall forthwith inform the sponsor. Within 90 days of the sponsor may submit detailed receipt of grounds for appeal, which the Agency shall refer to the Committee. The Committee shall consider whether its opinion should be revised at the following meeting. the opinion, 8. The Agency shall forthwith forward the final opinion of the Committee to the Commission, which shall adopt a decision within 30 days of receipt of the opinion. Where, in exceptional circumstances, the draft decision is not in accord- ance with the opinion of the Committee, the decision shall be adopted in accordance with the procedure laid down in Article 73 of Regulation (EEC) No 2309/93. The decision shall be notified to the sponsor and communicated to the Agency and to the competent authorities of the Member States. The designated medicinal product shall be entered in the 9. Community Register of Orphan Medicinal Products. Each year the sponsor shall submit to the Agency a 10. report on the state of development of the designated medicinal product. 11. To have the designation of an orphan medicinal product transferred to another sponsor, the holder of the designation shall make specific application to the Agency. In consultation with the Member States, the Agency and interested parties, the Commission shall draw up detailed guidelines on the form in which applications for transfer shall be made and the content of such applications and all the particulars of the new sponsor. L 18/4 EN Official Journal of the European Communities 22. 1. 2000 A designated orphan medicinal product shall be 12. removed from the Community Register of Orphan Medicinal Products: prejudice to the possibility of applying for a separate marketing authorisation for other indications outside the scope of this Regulation. (a) at the request of the sponsor; (b) if it is established before the market authorisation is granted that the criteria laid down in Article 3 are no longer met in respect of the medicinal product concerned; (c) at the end of the period of market exclusivity as laid down in Article 8. Article 6 Protocol assistance 1. The sponsor of an orphan medicinal product may, prior to the submission of an application for marketing author- isation. request advice from the Agency on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product, in accordance with Article 51(j) of Regulation (EEC) No 2309/93. 2. The Agency shall draw up a procedure on the develop- ment of orphan medicinal products, covering regulatory assis- tance for the definition of the content of the application for authorisation within the meaning of Article 6 of Regulation (EEC) No 2309/93. Article 7 Community marketing authorisation 1. The person responsible for placing on the market an orphan medicinal product may request that authorisation to place the medicinal product on the market be granted by the Community in accordance with the provisions of Regulation (EEC) No 2309/93 without having to justify that the medicinal product qualifies under Part B of the Annex to that Regulation. A special contribution from the Community, distinct 2. from that provided for in Article 57 of Regulation (EEC) No 2309/93, shall be allocated every year to the Agency. The contribution shall be used exclusively by the Agency to waive, in part or in total, all the fees payable under Community rules adopted pursuant to Regulation (EEC) No 2309/93. A detailed report of the use made of this special contribution shall be presented by the Executive Director of the Agency at the end of each year. Any surplus occurring in a given year shall be carried forward and deducted from the special contribution for the following year. 3. The marketing authorisation granted for an orphan medi- cinal product shall cover only those therapeutic indications which fulfil the criteria set out in Article 3. This is without Article 8 Market exclusivity 1. Where a marketing authorisation in respect of an orphan medicinal product is granted pursuant to Regulation (EEC) No 2309/93 or where all the Member States have granted marketing authorisations in accordance with the procedures for mutual recognition laid down in Articles 7 and 7a of Directive 65/65/EEC or Article 9(4) of Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (1), and without prejudice to intellectual property law or any other provision of Community law, the Community and the Member States shall not, for a period of 10 years, accept another application for a marketing authorisation, or grant a marketing authorisation or accept an application to extend an existing marketing authorisation, for the same therapeutic indi- cation, in respect of a similar medicinal product. 2. This period may however be reduced to six years if, at the end of the fifth year, it is established, in respect of the medi- cinal product concerned, that the criteria laid down in Article 3 are no longer met, inter alia, where it is shown on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity. To that end, a Member State shall inform the Agency that the criterion on the basis of which market exclusivity was granted may not be met and the Agency shall then initiate the procedure laid down in Article 5. The sponsor shall provide the Agency with the information necessary for that purpose. By way of derogation from paragraph 1, and without 3. prejudice to intellectual property law or any other provision of Community law, a marketing authorisation may be granted, for the same therapeutic indication, to a similar medicinal product if: (a) the holder of the marketing authorisation for the original orphan medicinal product has given his consent to the second applicant, or (b) the holder of the marketing authorisation for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product, or (c) the second applicant can establish in the application that the second medicinal product, although similar to the orphan medicinal product already authorised, is safer, more effective or otherwise clinically superior. The Commission shall adopt definitions of ‘similar medi- 4. cinal product’ and ‘clinical superiority’ in the form of an imple- menting Regulation in accordance with the procedure laid down in Article 72 of Regulation (EEC) No 2309/93. The Commission shall draw up detailed guidelines for the 5. application of this Article in consultation with the Member States, the Agency and interested parties. (1) OJ L 147, 9. 6. 1975, p. 13. Directive as last amended by Council Directive 93/39/EEC (OJ L 214, 24. 8. 1993, p. 22). 22. 1. 2000 EN Official Journal of the European Communities L 18/5 Article 9 Other incentives 1. Medicinal products designated as orphan medicinal prod- ucts under the provisions of this Regulation shall be eligible for incentives made available by the Community and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings provided for in framework programmes for research and tech- nological development. 2. Before 22 July 2000, the Member States shall communi- cate to the Commission detailed information concerning any measure they have enacted to support research into, and the development and availability of, orphan medicinal products or medicinal products that may be designated as such. That infor- mation shall be updated regularly. Before 22 January 2001, the Commission shall publish a 3. detailed inventory of all incentives made available by the Community and the Member States to support research into, and the development and availability of, orphan medicinal products. That inventory shall be updated regularly. Article 10 General report Before 22 January 2006, the Commission shall publish a general report on the experience acquired as a result of the application of this Regulation, together with an account of the public health benefits which have been obtained. Article 11 Entry into force This Regulation shall enter into force on the day of its publica- tion in the Official Journal of the European Communities. It shall apply as from the date of adoption of the implementing Regulations provided for in Article 3(2) and Article 8(4). This Regulation shall be binding in its entirety and directly applicable in all Member States. Done at Brussels, 16 December 1999. For the European Parliament The President N. FONTAINE For the Council The President K. HEMILÄ


title: Kommissionens forordning (EF) nr. 2654/1999 af 16. december 1999 om ændring af forordning (EØF) nr. 2921/90 om ydelse af støtte til skummetmælk med henblik på fremstilling af kasein og kaseinater

eurovoc_concepts:
aid system
food processing
milk by-product
skimmed milk

text: L 325/10 DA De Europæiske Fællesskabers Tidende 17. 12. 1999 KOMMISSIONENS FORORDNING (EF) Nr. 2654/1999 af 16. december 1999 om ændring af forordning (EØF) nr. 2921/90 om ydelse af støtte til skummetmælk med henblik på fremstilling af kasein og kaseinater KOMMISSIONEN FOR DE EUROPÆISKE FÆLLESSKABER HAR — UDSTEDT FØLGENDE FORORDNING: under henvisning til traktaten om oprettelse af Det Europæiske Fællesskab, Artikel 1 under henvisning til Rådets forordning (EF) nr. 1255/1999 af 17. maj 1999 om den fælles markedsordning for mælk og mejeriprodukter (1), særlig artikel 15, og I artikel 1 i forordning (EØF) nr. 2921/90 foretages følgende ændringer: 1) Indledningen af stk. 2 affattes således: Støtten ydes på basis af en skriftlig ansøgning fra »2. producenten af kasein og kaseinater til det kompetente organ i den medlemsstat, hvor kaseinet eller kaseinaterne er fremstillet. I ansøgningen anføres:« ud fra følgende betragtninger: 2) Som stk. 4 indsættes: (1) Forordning (EF) nr. 1255/1999 erstatter pr. 1. januar 2000 Rådets forordning (EØF) nr. 804/68 (2), senest ændret ved forordning (EF) nr. 1587/96 (3), og bl. a. Rådets forordning (EØF) nr. 987/68 af 15. juli 1968 om fastsættelse af almindelige regler for ydelse af støtte til skummetmælk, der er forarbejdet til kasein og kasei- nater (4), senest ændret ved forordning (EØF) nr. 1435/ tage hensyn til den nye ordning bør 90 (5). For at bestemmelserne i Kommissionens forordning (EØF) nr. 2921/90 af 10. oktober 1990 om ydelse af støtte til skummetmælk med henblik på fremstilling af kasein og kaseinater (6), senest ændret ved forordning (EF) nr. 2501/1999 (7), ændres. De produktdefinitioner, der er omfattet af i støtteordningen, bør derfor forordningen, og det bør fastlægges, hvilket organ ansø- geren skal indgive sin støtteansøgning til. Bestemmel- serne bør anvendes fra den 1. januar 2000; indsættes (2) Forvaltningskomitéen for Mælk og Mejeriprodukter har ikke afgivet udtalelse inden for den af formanden fast- satte frist — (1) EFT L 160 af 26. 6. 1999, s. 48. (2) EFT L 148 af 28. 6. 1968, s. 13. (3) EFT L 206 af 16. 8. 1996, s. 21. (4) EFT L 169 af 18. 7. 1968, s. 6. (5) EFT L 138 af 31. 5. 1990, s. 8. (6) EFT L 279 af 11. 10. 1990, s. 22. (7) EFT L 304 af 27. 11. 1999, s. 13. »4. I denne forordning forstås ved: a) skummetmælk: produktet fra malkning af en eller flere køer eller geder, til hvilket intet er tilsat, og som har været genstand for en delvis skumning, der har bragt fedtindholdet ned på højst 0,10 % b) råkasein: det produkt, der fremstilles af skummetmælk ved udfældning ved syrning med bakteriekultur eller ved hjælp af løbe eller andre mælkekoagulerende enzymer, og som er uopløseligt i vand, uanset om der først er foretaget en eventuel ionbytning eller koncentre- ring syre, c) kasein: det vaskede eller tørrede produkt, der fremstilles af råkasein eller af skummetmælk ved udfældning ved syrning med bakteriekultur eller ved hjælp af syre, løbe eller andre mælkekoagulerende enzymer, og som er uopløseligt i vand, uanset om der først er foretaget en eventuel ionbytning eller koncentrering d) kaseinater: de produkter, der fremstilles ved tørring af kasein eller råkasein, og som er behandlet med neutrali- seringsmidler. « Artikel 2 Denne forordning træder i kraft den 1. januar 2000. 17. 12. 1999 DA De Europæiske Fællesskabers Tidende L 325/11 Denne medlemsstat. forordning er bindende i alle enkeltheder og gælder umiddelbart i hver Udfærdiget i Bruxelles, den 16. december 1999. På Kommissionens vegne Franz FISCHLER Medlem af Kommissionen


title: PREGUNTA ESCRITA E-2485/99 de Karin Riis-Jørgensen (ELDR) a la Comisión. Ayudas en favor de la comunicación fija a través del Øresund.

text: C 374 E/4 Diario Oficial de las Comunidades Europeas ES 28. 12. 2000 En el caso concreto de Portugal, en 1993 se concedi(cid:243) al amparo de esta iniciativa un importe adicional de 30 millones de € que ya se ha pagado enteramente. La lista de los proyectos financiados en Portugal al amparo de esta iniciativa se remitarÆ a Su Seæor(cid:237)a y a la Secretar(cid:237)a General del Parlamento. (2000/C 374 E/004) PREGUNTA ESCRITA E-2485/99 de Karin Riis-Jłrgensen (ELDR) a la Comisi(cid:243)n (16 de diciembre de 1999) Asunto: Ayudas en favor de la comunicaci(cid:243)n fija a travØs del (cid:216)resund En relaci(cid:243)n con la puesta en funcionamiento de la comunicaci(cid:243)n fija a travØs del (cid:216)resund, ¿puede la Comisi(cid:243)n indicar si las autoridades danesas y/o suecas han notificado la concesi(cid:243)n de ayudas a la Administraci(cid:243)n Nacional de la Superestructura Ferroviaria sueca y a la correspondiente administraci(cid:243)n ferroviaria danesa, respectivamente, que deberÆn tener como consecuencia la reducci(cid:243)n de las tarifas ferroviarias correspondientes al actual pontazgo, es decir, una ayuda en favor de la explotaci(cid:243)n de la construcci(cid:243)n? ¿Puede, ademÆs, la Comisi(cid:243)n indicar si una ayuda nacional concedida para cubrir los gastos de pontazgo para las autoridades ferroviarias estatales constituye, a su entender, una distorsi(cid:243)n de la competencia en detrimento de los transbordadores que cubren el transporte de pasajeros a travØs del estrecho de (cid:216)resund? ¿Considera la Comisi(cid:243)n que semejante situaci(cid:243)n es conforme a las disposiciones del Tratado relativas al reparto de las ayudas nacionales? Respuesta de la Sra. de Palacio en nombre de la Comisi(cid:243)n (9 de febrero de 2000) El 30 de septiembre de 1998 las autoridades danesas notificaron a la Comisi(cid:243)n un rØgimen de ayudas estatales relativo a una subvenci(cid:243)n de carÆcter medioambiental para el transporte de mercanc(cid:237)as por ferrocarril. La base jur(cid:237)dica de este rØgimen es la ley danesa 289 de 18 de mayo de 1998 que establece un marco para las operaciones de transporte por ferrocarril en Dinamarca y contiene, entre otras cosas, disposiciones en materia de pagos de tarifas por la utilizaci(cid:243)n de la red ferroviaria danesa y de subvenciones para el desarrollo de proyectos ferroviarios por motivos medioambientales. El 21 de abril de 1999, la Comisi(cid:243)n consider(cid:243) que el rØgimen danØs de ayuda estatal era compatible con el mercado comœn. A la hora de decidir, la Comisi(cid:243)n tuvo en cuenta que importe de la subvenci(cid:243)n era significativamente inferior al importe estimado de los costes externos no cubiertos del transporte por carretera, que el rØgimen de ayuda estÆ abierto a cualquier empresa de transporte de mercanc(cid:237)as por ferrocarril y que excluye el trÆfico en trÆnsito para salvaguardar los intereses del transporte mar(cid:237)timo, otro modo de transporte respetuoso con el medio ambiente. Cualquier medida nacional que reduzca cualquier tipo de tasa a las empresas de transporte puede, en principio, afectar negativamente la competitividad entre los modos de transporte, y por tanto podr(cid:237)a considerarse una ayuda estatal con arreglo al Tratado de la CE por cuanto afecta al comercio entre los Estados miembros. MÆs concretamente, la ayuda estatal en favor del transporte ferroviario puede afectar la competitividad del transporte mar(cid:237)timo y viceversa, cuando tal ayuda subvenciona un segmento del mercado (una ruta) para el cual el tren y el barco compiten entre si. Para poder evaluar la compatibilidad de tal subvenci(cid:243)n con el Tratado de la CE, la Comisi(cid:243)n debe ser debidamente notificada de tales medidas de conformidad con el apartado 3 del Art(cid:237)culo 88 (antiguo Art(cid:237)culo 93) del Tratado de la CE. Sin embargo, no es posible ofrecer una respuesta apropiada sobre ese punto sin disponer previamente de toda la informaci(cid:243)n necesaria para tal evaluaci(cid:243)n


title: QUESTION ÉCRITE E-2470/99 posée par Daniela Raschhofer (NI) à la Commission. Déclaration de Prodi: Brèche dans la solidarité européenne.

eurovoc_concepts:
Austria
President of the Commission
Treaty on European Union
human rights
national election
speech

text: C 219 E/172 Journal officiel des CommunautØs europØennes FR 1. 8. 2000 (2000/C 219 E/219) QUESTION (cid:201)CRITE E-2470/99 posØe par Daniela Raschhofer (NI) (cid:224) la Commission (16 dØcembre 1999) Objet: DØclaration de Prodi: «BrŁche dans la solidaritØ europØenne» Selon les informations parues dans la presse, le prØsident de la Commission aurait, lors d(cid:146)une cØrØmonie officielle (cid:224) Marzobotto (Italie) ØvoquØ les succŁs Ølectoraux de la droite «en Autriche, en Italie et en Suisse» pour mettre en garde contre la brŁche survenue dans la solidaritØ europØenne. La Commission peut-elle indiquer: (cid:129) Est-il possible d(cid:146)avoir communication du texte original de l(cid:146)allocution? (cid:129) Comment doit-on comprendre cette mise en garde? (cid:129) (cid:192) quels partis de droite le prØsident fait-il allusion? (cid:129) Ces partis sont-ils des partis dØmocratiques? (cid:129) Pourquoi le PrØsident de la Commission estime-t-il que l(cid:146)Europe traverse une «crise» du fait des succŁs Ølectoraux en Autriche? (cid:129) Le PrØsident peut-il dØcrire de fa(cid:231)on plus prØcise la «crise» (cid:224) laquelle il fait allusion? (cid:129) De quelle maniŁre cette crise se manifeste-t-elle? (cid:129) De quelles informations le PrØsident dispose-t-il pour estimer que les succŁs Ølectoraux en Autriche ont provoquØ une brŁche dans la solidaritØ europØenne? (cid:129) Comment le PrØsident de la Commission en vient-il (cid:224) penser que les succŁs Ølectoraux en Autriche ont provoquØ une brŁche dans la solidaritØ europØenne? RØponse donnØe par M. Prodi au nom de la Commission (28 janvier 2000) L(cid:146)allocution (cid:224) laquelle se rØfŁre l(cid:146)Honorable Parlementaire, prononcØe sans base Øcrite, n(cid:146)est malheureuse- ment pas disponible. Si, en rŁgle gØnØrale, il n(cid:146)appartient pas (cid:224) la Commission de s(cid:146)immiscer dans les affaires internes des (cid:201)tats membres, il n(cid:146)est cependant pas inutile de rappeler le principe de la solidaritØ qui figure au prØambule du traitØ sur l(cid:146)Union europØenne. Il y a lieu de rappeler Øgalement l(cid:146)article 6, paragraphe 1 de ce dernier: «l(cid:146)Union est fondØe sur les principes de la libertØ, de la dØmocratie, du respect des droits de l(cid:146)homme et des libertØs fondamentales, ainsi que de l(cid:146)(cid:201)tat de droit, principes qui sont communs aux (cid:201)tats membres». Le PrØsident Prodi est trŁs attachØ au principe de solidaritØ et c(cid:146)est (cid:224) la lumiŁre du traitØ qu(cid:146)il faut comprendre le discours auquel il est fait rØfØrence. (2000/C 219 E/220) QUESTION (cid:201)CRITE E-2471/99 posØe par Mathieu Grosch (PPE-DE) (cid:224) la Commission Objet: Agences concernant les programmes europØens en Belgique (16 dØcembre 1999) 1. Est-il exact que la Commission envisage de rØunir en une seule agence, qui serait compØtente pour l(cid:146)ensemble de la Belgique, les trois agences (des communautØs flamande, francophone et germanophone) compØtentes pour l(cid:146)exØcution des programmes europØens de formation et de perfectionnement? 2. Combien de temps le systŁme des trois agences subsistera-t-il?


title: Risoluzione del Parlamento europeo sull'Indonesia

eurovoc_concepts:
East Timor
Indonesia
Moluccas
government violence
human rights
international sanctions
paramilitary force

formats: pdf print

text: 18. 10. 2000 IT Gazzetta ufficiale delle Comunità europee C 296/199 Giovedì 16 dicembre 1999 23. osserva che la nuova politica di mobilità del personale della categoria A costituisce, in linea di principio, una buona misura per rendere il Segretariato generale del Parlamento più dinamico, ma sottoli- nea che, senza un maggiore sforzo sostanziale in materia di formazione professionale, ad esempio per quanto riguarda l’ambiente, i trasporti, l’agricoltura, ecc. , vi sarà un’enorme perdita di capitale umano; incarica il suo Segretario generale di presentare entro il 31 marzo 2000 una relazione in cui vengano proposte le misure volte a compensare questa perdita di capitale umano a breve e medio termine; 24. sottolinea con vigore che la politica di mobilità, di promozione e di valutazione del personale deve costituire un insieme coerente; insiste sul fatto che le promozioni, specialmente dei funzionari di grado A1 e A2, devono essere rigorosamente fondate sulle prestazioni professionali e sulle capacità personali e manageriali; confida nella presentazione da parte del Segretario generale, entro il 31 marzo 2000, di una relazione sull’attuazione coerente della politica di mobilità, promozione e valutazione; confida in partico- lare nel fatto che per quanto riguarda la valutazione la relazione si occuperà anche della formazione di coloro che la effettuano, dei criteri di valutazione e delle possibilità che i funzionari hanno di valutare a loro volta coloro da cui vengono valutati; 25. è favorevole a mantenere l’accordo tra il Mediatore e il Parlamento per quanto riguarda le questioni amministrative, finanziarie e logistiche; sottolinea che, anche se il bilancio del Mediatore diventerà una sezione indipendente del bilancio generale delle Comunità a partire dal bilancio 2000 in poi, ciò non dovrebbe accompagnarsi ad un incremento del personale nel settore dell’amministrazione, del bilancio e delle finanze; * * * 26. incarica la sua Presidente di dichiarare l’atto finanziario bilancio dell’Unione europea; incarica la sua Presidente di trasmettere le presenti decisioni di bilancio al Consiglio, alla Commis- 27. sione, alle istituzioni nonché agli organi consultivi interessati. 9. Indonesia B5-0339, 0350, 0366, 0377 e 0382/1999 Risoluzione del Parlamento europeo sull’Indonesia Il Parlamento europeo, / viste le sue precedenti risoluzioni su Timor orientale e Indonesia, A. B. considerando che il 16 settembre 1999 il Consiglio ha adottato la posizione comune 1999/624/CFSP che prevede misure restrittive nei confronti della Repubblica di Indonesia, inclusi un embargo sulle armi e la sospensione della cooperazione militare bilaterale tra l’Indonesia e gli Stati membri dell’UE, considerando che l’11 ottobre 1999 il Consiglio ha adottato il regolamento (CE) n. 2158/1999 che vieta fra l’altro la vendita di talune attrezzature specifiche che potrebbero essere utilizzate per la repressione interna, C. considerando che la posizione comune e il regolamento scadranno il 17 gennaio 2000, D. E. considerando che l’esercito indonesiano, incluso il corpo speciale Kopassus, continua a commettere violazioni dei diritti dell’uomo e atti di repressione nel distretto di Aceh, nelle Isole Molucche e nell’ Irian occidentale; che nessun membro delle forze di sicurezza ha dovuto rendere conto delle migliaia di violazioni commesse in tali zone, considerando che l’esercito indonesiano non ha disarmato e sciolto le forze della milizia che conti- nuano a terrorizzare oltre 100. 000 sfollati di Timor orientale intrappolati a Timor occidentale, osta- colando gli sforzi delle agenzie delle Nazioni Unite volti a salvaguardarne la salute e a farli rientrare a Timor orientale, C 296/200 Gazzetta ufficiale delle Comunità europee IT 18. 10. 2000 Giovedì 16 dicembre 1999 F. considerando che le autorità indonesiane e l’esercito in particolare sono assolutamente contrari a coo- perare con una commissione internazionale d’inchiesta creata dalle Nazioni Unite con l’incarico di indagare sui crimini contro l’umanità commessi a Timor orientale, sollecita il nuovo governo indonesiano a trovare una soluzione pacifica alla situazione nel distretto di 1. Aceh, nelle Isole Molucche, nell’Irian occidentale e in altre parti dell’Indonesia; chiede al governo indonesiano di chiamare a rendere conto del loro operato i responsabili di viola- 2. zioni dei diritti dell’uomo nel distretto di Aceh, nelle Isole Molucche, nell’Irian occidentale e in altri parti del paese, nonché a Timor orientale, siano esse state commesse da civili, da membri della milizia o da militari; invita tutte le parti interessate a collaborare pienamente alle indagini e esorta il governo indone- siano a sciogliere il corpo speciale Kopassus; 3. riconosce che la ripresa delle esportazioni nella Repubblica di Indonesia di armi e di altre attrezzature vietate, nonché la ripresa della cooperazione militare, manderanno alle forze armate indonesiane il segnale che sono state riabilitate, legittimando la repressione che continuano ad attuare nel governo interno del- l’Indonesia; 4. chiede pertanto al Consiglio di esaminare possibili adeguamenti della posizione comune e del rego- lamento summenzionati alla luce degli sviluppi in Indonesia, incluso il problema degli sfollati da Timor orientale a Timor occidentale, al fine di prolungare la validità dei due strumenti oltre il 17 gennaio 2000; 5. incarica la sua Presidente di trasmettere la presente risoluzione alla Commissione, al Consiglio, ai Parlamenti degli Stati membri, al Segretario generale dell’ONU, al governo dell’Indonesia e al leader del CNRT Xanana Gusmao. 10. Processo di pace in Sierra Leone B5-0333, 0340, 0352 e 0367/1999 Risoluzione del Parlamento europeo sul processo di pace in Sierra Leone Il Parlamento europeo, / vista la dichiarazione della Presidenza del 15 luglio 1999 sull’Accordo di pace con la Sierra Leone, / vista l’azione comune adottata dal Consiglio sul contributo dell’UE volto a combattere l’accumulo destabilizzante di armi leggere e di piccolo calibro, A. B. C. D. considerando che gli attacchi dei ribelli contro la popolazione civile, compresi le uccisioni, gli stupri e i sequestri intenzionali e arbitrari di civili, nel corso degli ultimi tre mesi sono aumentati nonostante l’Accordo di pace, firmato dal governo della Sierra Leone e dai rappresentanti del RUF (Fronte Rivolu- zionario Unito) nel Togo il 7 luglio 1999, considerando che l’Accordo di pace di Lomé del 7 luglio 1999 offre quella che fino ad ora costituisce la migliore opportunità per giungere ad una soluzione pacifica della guerra civile che ha dilaniato la Sierra Leone negli ultimi otto anni, e accogliendo con favore i progressi compiuti nell’attuazione di misure anticorruzione, di riforme politiche e nel settore della sicurezza, nonché di iniziative volte alla ricostruzione delle infrastrutture civili, considerando che l’Accordo di pace aveva lo scopo di porre fine ad un conflitto che ha causato soffe- renze atroci alla popolazione della Sierra Leone nonché migliaia di vittime tra i civili, sconvolgendo la Comunità internazionale per le atrocità commesse su vasta scala contro le donne e i bambini, considerando che migliaia di bambini hanno partecipato attivamente alla violenza in qualità di soldati, mentre altri sono stati colpiti dalla massiccia campagna di amputazione delle braccia del RUF, in seguito alla quale circa 10. 000 persone sono rimaste mutilate,


title: SKRIFTLIG FORESPØRGSEL E-2428/99 af Piia-Noora Kauppi (PPE-DE) til Kommissionen. Fritagelse af heste til konkurrence- og fritidsbrug for veterinærbestemmelser.

text: 8. 8. 2000 DA De Europ(cid:230)iske F(cid:230)llesskabers Tidende C 225 E/131 (2000/C 225 E/141) SKRIFTLIG FORESP(cid:216)RGSEL E-2421/99 af Sebastiano Musumeci (UEN) til Kommissionen (16. december 1999) Om: Nyt honningdirektiv, der skader biavlerne Kommissionen er i f(cid:230)rd med at vedtage et nyt direktiv om honning til erstatning for direktiv 74/409 (1), som i sin foreliggende skikkelse vil skade aktłrerne i sektoren voldsomt. Mener Kommissionen ikke p(cid:229) denne baggrund, at vedtagelsen af den nye retsakt błr uds(cid:230)ttes, s(cid:229) der sikres en mere indg(cid:229)ende behandling af de italienske og europ(cid:230)iske biavleres legitime krav, der is(cid:230)r tager sigte p(cid:229) at opn(cid:229): 1. 2. at honningproduktionen igen betragtes som et landbrugserhverv, og at der ikke gives efter for konservesindustriens lobbyvirksomhed, idet konservesindustrien til stadighed forsłger at sl(cid:230)kke p(cid:229) kvalitetskravene og de obligatoriske oplysninger p(cid:229) etiketterne; at de enkelte stater f(cid:229)r mulighed for at beskytte honningen som et produkt, der udelukkende fremstilles af blomsternektar, og forhindre, at der p(cid:229) det europ(cid:230)iske marked s(cid:230)lges honning og blandingsprodukter fra tredjelande, ofte med medlemsstaters medvirken? (1) EFT L 221 af 12. 8. 1974, s. 10. Svar afgivet p(cid:229) Kommissionens vegne af Erkki Liikanen (25. januar 2000) I 1996 forelagde Kommissionen et forslag til direktiv (1) med henblik p(cid:229) at forenkle og erstatte R(cid:229)dets juli 1974 vedrłrende honning (2). Under udarbejdelsen af forslaget og i direktiv 74/409/E(cid:216)F af 22. forbindelse med de derp(cid:229) fłlgende drłftelser tog Kommissionen (cid:129) inden for rammerne af det mandat, som den havde f(cid:229)et af Det Europ(cid:230)iske R(cid:229)d i Edinburgh (cid:129) hensyn til f(cid:230)llesskabsinteresserne hos alle de berłrte parter. 1. I forslaget til honningdirektivet er der en definition af honning, og der er fastsat en r(cid:230)kke kriterier for sammens(cid:230)tningen, som skal opfyldes ved fremstilling af honning b(cid:229)de inden for og uden for F(cid:230)llesskabet, for at produktet kan forhandles under denne betegnelse. i honningdirektivet. Efter en udtalelse fra Europa-Parlamentet, der blev afgivet 2. Det ville alts(cid:229) v(cid:230)re mod de regler, der g(cid:230)lder for samhandelen inden for EF og internationalt at mods(cid:230)tte sig indfłrsel af honning fra tredjelande, hvis den p(cid:229)g(cid:230)ldende honning opfylder de regler, der er fastsat i maj 1999, besluttede Kommissionen at (cid:230)ndre sit forslag for at głre det obligatorisk med en oprindelsesangivelse p(cid:229) etiketten, n(cid:229)r honningen hidrłrer fra et land uden for F(cid:230)llesskabet. Under młderne i R(cid:229)det har visse medlemsstater rejst spłrgsm(cid:229)l om, hvordan man skulle forhold sig, n(cid:229)r det drejede sig om blandinger af EF-produceret honning og honning produceret uden for F(cid:230)llesskabet. Dette spłrgsm(cid:229)l er endnu ikke afklaret. (1) (2) EFT C 378 af 13. 12. 1996. EFT L 221 af 12. 8. 1974. (2000/C 225 E/142) SKRIFTLIG FORESP(cid:216)RGSEL E-2428/99 af Piia-Noora Kauppi (PPE-DE) til Kommissionen (16. december 1999) Om: Fritagelse af heste til konkurrence- og fritidsbrug for veterin(cid:230)rbestemmelser En hest klassificeres i EU som et produktionsdyr, som af hensyn til kłdkvaliteten ikke m(cid:229) gives visse former for medicin. De seneste fłdevareskandaler har imidlertid gjort myndighederne forsigtige, og veterin(cid:230)rbestemmelserne skal overholdes, selvom kłdet fra dyret ikke ender som fłdevarer til mennesker. C 225 E/132 De Europ(cid:230)iske F(cid:230)llesskabers Tidende DA 8. 8. 2000 I Finland er en hest snarere et dyr, der anvendes til konkurrence og fritidsaktiviteter. Kun under halvdelen af hestene slagtes, og kun en brłkdel af disse heste anvendes i levnedsmiddelindustrien. Det er derfor meget vigtigt, at heste til konkurrence- og fritidsbrug fritages for veterin(cid:230)rbestemmelserne. Kommissionen deler (cid:229)benbart min opfattelse, og den har udarbejdet et forslag herom til R(cid:229)det. Da sagen til trods for dette synes at tr(cid:230)kke i langdrag, bedes Kommissionen oplyse, Hvad er Kommissionens tidsplan for at fremme, at der skelnes mellem heste til konkurrence- og 1. fritidsbrug og heste, der er klassificeret som produktionsdyr? 2. S(cid:229)fremt Kommissionens forslag i forbindelse med sagen tr(cid:230)kker i langdrag, hvordan kan heste til konkurrence- og fritid p(cid:229) nuv(cid:230)rende tidspunkt s(cid:229) medicineres, n(cid:229)r der endnu ikke er fastsat maksimale gr(cid:230)nsev(cid:230)rdier (MRL-v(cid:230)rdier)for de nłdvendige l(cid:230)gemidler? Svar afgivet p(cid:229) Kommissionens vegne af Erkki Liikanen (28. januar 2000) P(cid:229) grundlag af en positiv udtalelse (med kvalificeret flertal) p(cid:229) młdet i en f(cid:230)lles st(cid:229)ende zooteknisk og veterin(cid:230)r komitØ den 8. december 1999 vedtog Kommissionen en beslutning om et identifikations- dokument (pas), der skal ledsage registrerede hovdyr til opdr(cid:230)t og som brugsdyr (1) p(cid:229) grundlag af R(cid:229)dets direktiv 90/426/E(cid:216)F af 26. juni 1990 om dyresundhedsm(cid:230)ssige betingelser for enhovede dyrs bev(cid:230)gelser og indfłrsel af enhovede dyr fra tredjelande (2) og R(cid:229)dets direktiv 90/427/E(cid:216)F af 26. juni 1990 om zootekniske og genealogiske betingelser for samhandelen inden for F(cid:230)llesskabet med enhovede dyr (2). I det for hovdyr til opdr(cid:230)t og som brugsdyr planlagte identifikationsdokument bruges en del af de oplysninger, som omfattes af det internationalt anerkendte pas for registrerede hovdyr, som beslutning 93/ 623/E(cid:216)F (3) indeholder bestemmelser om. Et s(cid:230)rligt afsnit, som skal tilfłjes det identifikationsdokument, der skal ledsage registrerede hovdyr og hovdyr til opdr(cid:230)t og som brugsdyr, giver mulighed for at foretage en markering for hovdyr, som ikke er bestemt til slagtning til konsum, og dyr, som er bestemt til slagtning, p(cid:229) betingelse af, at behandling med medicin, som indeholder substanser, der ikke er omfattet af bilag I, II juni 1990 om en f(cid:230)lles fremgangsm(cid:229)de for eller III i R(cid:229)dets forordning (E(cid:216)F) nr. 2377/90 af 26. fasts(cid:230)ttelse af maksimalgr(cid:230)nsev(cid:230)rdier for restkoncentrationer af veterin(cid:230)rmedicinske pr(cid:230)parater i animal- ske levnedsmidler (4), registreres og en generel tilbageholdelsesperiode p(cid:229) seks m(cid:229)neder overholdes. Fra den 1. januar 2000 er det inden for F(cid:230)llesskabet forbudt at behandle dyr, der bruges til fłdevarefrem- stilling, med medicin, som indeholder farmakologisk aktive substanser, som ikke er omfattet af bilag I, II og III i forordning (E(cid:216)F) nr. 2377/90. Derfor kan behandling af heste med substanser, som ikke er omfattet af bilagene, kun finde sted eller ordineres, n(cid:229)r dyrl(cid:230)gen har sikret sig, at det i det nye afsnit i dyrets identifikationsdokument er markeret, at det enten ikke er bestemt til slagtning, eller at det er bestemt til slagtning p(cid:229) ovenn(cid:230)vnte betingelser. N(cid:229)r hovdyr transporteres til slagteriet, skal identifikationsdokumentet ved en undersłgelse fłr slagtningen kontrolleres af den ansvarlige dyrl(cid:230)ge p(cid:229) slagteriet for at fastsl(cid:229) dyrets identitet og kontrollere registre- ringen af den medicinske behandling med henblik p(cid:229) at sikre, at den kr(cid:230)vede tilbageholdelsesperiode er udlłbet. (1) (2) (3) (4) (endnu ikke offentliggjort). EFT L 296 af 27. 10. 1990. EFT L 298 af 3. 12. 1993. EFT L 87 af 2. 4. 1992. (2000/C 225 E/143) SKRIFTLIG FORESP(cid:216)RGSEL E-2431/99 af Roberta Angelilli (NI) til Kommissionen (16. december 1999) Om: M(cid:229)l 2 og regionen Lazio EU(cid:146)s oml(cid:230)gning for nylig af m(cid:229)lomr(cid:229)derne og dermed af anvendelsen af strukturfondene har medfłrt en r(cid:230)kke stridsspłrgsm(cid:229)l i regionen Lazio i Italien p(cid:229) grund af den nye fordeling af m(cid:229)lomr(cid:229)derne. Bl. a. synes


title: SCHRIFTELIJKE VRAAG E-2376/99 van John Cushnahan (PPE-DE) aan de Commissie. Esperanto.

eurovoc_concepts:
EU institution
European Commission
official language
powers of the institutions (EU)

text: C 203 E/170 Publicatieblad van de Europese Gemeenschappen NL 18. 7. 2000 De Commissie heeft ook M€ 10 vastgelegd voor het nieuwe trust fonds van het overgangsbestuur op Oost- Timor (Untaet) voor de allernoodzakelijkste initiatieven en organisatorische steun met het oog op het overgangsbestuur en de humanitaire hulp in de toekomst. Uit een oogpunt van ontwikkeling zal een samenhangende herstel- en wederopbouwstrategie voor het vrij kleine grondgebied van Oost-Timor een intensieve co(cid:246)rdinatie tussen alle betrokken partijen vereisen. De recente gezamenlijke evaluatiemissie, die door de Wereldbank werd geleid maar waaraan de Commissie actief heeft deelgenomen, zal een basis leggen voor de uitwerking van een blauwdruk voor concrete actie op lange termijn, die op 17 december 1999 op een vergadering van donors te Tokyo wordt besproken. De Commissie is momenteel bezig het samenvattende verslag van die gezamenlijke missie te evalueren, teneinde na te gaan op welke gebieden de Gemeenschap het beste kan bijdragen om haar hulp zo efficiºnt en doeltreffend mogelijk te verlenen. (2000/C 203 E/219) SCHRIFTELIJKE VRAAG E-2376/99 van John Cushnahan (PPE-DE) aan de Commissie (16 december 1999) Betreft: Esperanto Kan de Commissie overwegen om Esperanto een plaats te geven als een van de werktalen van de EU? Antwoord van de heer Prodi namens de Commissie (6 januari 2000) Op grond van artikel 290 van het EG-Verdrag wordt de regeling van het taalgebruik door de instellingen der Gemeenschap,. , door de Raad met eenparigheid van stemmen vastgesteld. (2000/C 203 E/220) SCHRIFTELIJKE VRAAG P-2389/99 van Gorka Kn(cid:246)rr Borr(cid:224)s (Verts/ALE) aan de Commissie Betreft: Dreigementen in verband met Europese investeringen in Cuba (1 december 1999) Volgens informatie uit officiºle bron oefenen de Amerikaanse autoriteiten de laatste tijd druk uit op de Spaanse onderneming Sol-MeliÆ in verband met investeringen van dit bedrijf in Cuba. Is de Commissie hiervan op de hoogte? Deelt de Commissie de mening dat elke vorm van pressie op ondernemingen van een lidstaat een duidelijk teken is van vijandschap tegenover de Europese Unie als geheel? Heeft de Commissie stappen ondernomen om informatie over deze kwestie in te winnen? Is de Commissie voornemens (cid:129) als de uitgeoefende pressie wordt bevestigd (cid:129) maatregelen te nemen in het kader van de overeenkomsten die de Europese Unie en de Verenigde Staten hebben gesloten? Antwoord van de heer Patten namens de Commissie (16 december 1999) Het is de Commissie bekend dat de Amerikaanse autoriteiten in het kader van de wet Helms-Burton onderzoek hebben verricht naar de activiteiten in Cuba van bepaalde ondernemingen uit de Gemeenschap, waaronder Sol-MeliÆ